

Evaluation of the mRNA-1273 Vaccine against SARS-CoV

New England Journal of Medicine

383, 1544-1555

DOI: [10.1056/nejmoa2024671](https://doi.org/10.1056/nejmoa2024671)

Citation Report

#	ARTICLE	IF	CITATIONS
1	COVID-19: Current Developments and Further Opportunities in Drug Delivery and Therapeutics. <i>Pharmaceutics</i> , 2020, 12, 945.	2.0	14
2	Prospects for a safe COVID-19 vaccine. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	204
3	Interim analysis of an open-label randomized controlled trial evaluating nasal irrigations in non-hospitalized patients with coronavirus disease 2019. <i>International Forum of Allergy and Rhinology</i> , 2020, 10, 1325-1328.	1.5	32
4	A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2. <i>Cell</i> , 2020, 183, 169-184.e13.	13.5	446
5	Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. <i>New England Journal of Medicine</i> , 2020, 383, 2427-2438.	13.9	1,242
6	Feline infectious peritonitis (FIP) and coronavirus disease 19 (COVID-19): Are they similar?. <i>Transboundary and Emerging Diseases</i> , 2021, 68, 1786-1799.	1.3	31
7	Viruses That Can and Cannot Coexist With Humans and the Future of SARS-CoV-2. <i>Frontiers in Microbiology</i> , 2020, 11, 583252.	1.5	18
8	REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. <i>Science</i> , 2020, 370, 1110-1115.	6.0	476
9	Rapid Response Subunit Vaccine Design in the Absence of Structural Information. <i>Frontiers in Immunology</i> , 2020, 11, 592370.	2.2	11
10	Novel corona virus (COVID-19) pandemic: current status and possible strategies for detection and treatment of the disease. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 1275-1298.	2.0	21
11	SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. <i>Lancet</i> , The, 2020, 396, 1595-1606.	6.3	511
12	SARS-CoV-2 vaccines in development. <i>Nature</i> , 2020, 586, 516-527.	13.7	1,659
14	Animal models for COVID-19. <i>Nature</i> , 2020, 586, 509-515.	13.7	705
15	Warp Speed for Coronavirus Disease 2019 (COVID-19) Vaccines: Why Are Children Stuck in Neutral?. <i>Clinical Infectious Diseases</i> , 2021, 73, 336-340.	2.9	70
16	The immunology of SARS-CoV-2 infections and vaccines. <i>Seminars in Immunology</i> , 2020, 50, 101422.	2.7	85
17	Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function. <i>Advances in Chronic Kidney Disease</i> , 2020, 27, 434-441.	0.6	5
18	SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation. <i>Immunity</i> , 2020, 53, 1281-1295.e5.	6.6	285
19	Low toxicity and high immunogenicity of an inactivated vaccine candidate against COVID-19 in different animal models. <i>Emerging Microbes and Infections</i> , 2020, 9, 2606-2618.	3.0	28

#	ARTICLE	IF	CITATIONS
20	Selection of animal models for COVID-19 research. <i>VirusDisease</i> , 2020, 31, 453-458.	1.0	24
21	Efforts at COVID-19 Vaccine Development: Challenges and Successes. <i>Vaccines</i> , 2020, 8, 739.	2.1	98
22	Approaches and Challenges in SARS-CoV-2 Vaccine Development. <i>Cell Host and Microbe</i> , 2020, 28, 364-370.	5.1	98
23	Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 951.	3.8	671
24	Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models. <i>Nature Reviews Immunology</i> , 2020, 20, 727-738.	10.6	107
25	Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area. <i>MBio</i> , 2020, 11, .	1.8	99
26	Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. <i>Nature Microbiology</i> , 2020, 5, 1598-1607.	5.9	1,115
27	A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone. <i>Scientific Reports</i> , 2020, 10, 18149.	1.6	90
28	Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	1.8	494
29	Vaccine Against Covid-19 Disease – Present Status of Development. <i>Indian Journal of Pediatrics</i> , 2020, 87, 810-816.	0.3	38
30	Cell and animal models of SARS-CoV-2 pathogenesis and immunity. <i>DMM Disease Models and Mechanisms</i> , 2020, 13, .	1.2	46
31	What can we expect from first-generation COVID-19 vaccines?. <i>Lancet, The</i> , 2020, 396, 1467-1469.	6.3	94
32	Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy. <i>Cell</i> , 2020, 183, 1013-1023.e13.	13.5	227
33	Vaccines targeting SARS-CoV-2 tested in humans. <i>Nature Medicine</i> , 2020, 26, 1336-1338.	15.2	7
34	Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19). <i>Toxicologic Pathology</i> , 2020, 48, 800-809.	0.9	29
35	Frontiers in the COVID-19 vaccines development. <i>Experimental Hematology and Oncology</i> , 2020, 9, 24.	2.0	15
36	A SARS-CoV-2 mRNA Vaccine – Preliminary Report. <i>New England Journal of Medicine</i> , 2020, 383, 1190-1192.	13.9	26
37	SARS-CoV-2 genomic and subgenomic RNAs in diagnostic samples are not an indicator of active replication. <i>Nature Communications</i> , 2020, 11, 6059.	5.8	254

#	ARTICLE	IF	CITATIONS
38	Development of vaccines and antivirals for combating viral pandemics. <i>Nature Biomedical Engineering</i> , 2020, 4, 1128-1133.	11.6	66
39	COVID-19: Coronavirus Vaccine Development Updates. <i>Frontiers in Immunology</i> , 2020, 11, 602256.	2.2	143
40	RNA Vaccines: A Suitable Platform for Tackling Emerging Pandemics?. <i>Frontiers in Immunology</i> , 2020, 11, 608460.	2.2	54
41	Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. <i>Science Immunology</i> , 2020, 5, .	5.6	244
42	Nanotechnology shows promise for next-generation vaccines in the fight against COVID-19. <i>MRS Bulletin</i> , 2020, 45, 981-982.	1.7	9
43	NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. <i>Vaccine</i> , 2020, 38, 7892-7896.	1.7	200
44	Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment. <i>Journal of Biological Chemistry</i> , 2021, 296, 100025.	1.6	43
45	Targeted Nanotherapeutics for Respiratory Diseases: Cancer, Fibrosis, and Coronavirus. <i>Advanced Therapeutics</i> , 2021, 4, 2000203.	1.6	16
46	Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 39-51.	4.6	923
47	T cell immunity to SARS-CoV-2 following natural infection and vaccination. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 211-217.	1.0	88
48	New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates. <i>Vaccine</i> , 2021, 39, 197-201.	1.7	67
49	SARS-CoV-2â€“Specific Neutralizing Antibody Responses in Norwegian Health Care Workers After the First Wave of COVID-19 Pandemic: A Prospective Cohort Study. <i>Journal of Infectious Diseases</i> , 2021, 223, 589-599.	1.9	31
50	Racing to immunity: Journey to a COVIDâ€“19 vaccine and lessons for the future. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3408-3424.	1.1	16
51	Development of SARS-CoV-2 vaccines: challenges, risks, and the way forward. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1635-1649.	1.4	14
52	Biomimetic Nanomaterial Strategies for Virus Targeting: Antiviral Therapies and Vaccines. <i>Advanced Functional Materials</i> , 2021, 31, 2008352.	7.8	25
53	COVID-19: A review of therapeutic strategies and vaccine candidates. <i>Clinical Immunology</i> , 2021, 222, 108634.	1.4	180
54	Clinical Outcomes Of A COVID-19 Vaccine: Implementation Over Efficacy. <i>Health Affairs</i> , 2021, 40, 42-52.	2.5	147
55	Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials. <i>Annals of Internal Medicine</i> , 2021, 174, 221-228.	2.0	86

#	ARTICLE	IF	CITATIONS
56	COVID-19 Vaccines May Not Prevent Nasal SARS-CoV-2 Infection and Asymptomatic Transmission. Otolaryngology - Head and Neck Surgery, 2021, 164, 305-307.	1.1	111
57	Viral targets for vaccines against COVID-19. Nature Reviews Immunology, 2021, 21, 73-82.	10.6	832
58	Identifying and repurposing antiviral drugs against severe acute respiratory syndrome coronavirus 2 with in silico and in vitro approaches. Biochemical and Biophysical Research Communications, 2021, 538, 137-144.	1.0	12
59	Passive inhaled mRNA vaccination for SARS-Cov-2. Medical Hypotheses, 2021, 146, 110417.	0.8	2
60	Non-viral COVID-19 vaccine delivery systems. Advanced Drug Delivery Reviews, 2021, 169, 137-151.	6.6	152
61	Self-amplifying RNA vaccines for infectious diseases. Gene Therapy, 2021, 28, 117-129.	2.3	212
62	Hybridization Networks of mRNA and Branched RNA Hybrids. ChemBioChem, 2021, 22, 924-930.	1.3	2
63	Informed consent disclosure to vaccine trial subjects of risk of COVID-19 vaccines worsening clinical disease. International Journal of Clinical Practice, 2021, 75, e13795.	0.8	21
64	Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, Phase I trial. Emerging Microbes and Infections, 2021, 10, 1589-1597.	3.0	41
65	Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses. Vaccines, 2021, 9, 73.	2.1	24
67	A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques. Emerging Microbes and Infections, 2021, 10, 342-355.	3.0	37
68	Safety in Endoscopy for Patients and Healthcare Workers During the COVID-19 Pandemic. Techniques and Innovations in Gastrointestinal Endoscopy, 2021, 23, 170-178.	0.4	9
69	An Update on Self-Amplifying mRNA Vaccine Development. Vaccines, 2021, 9, 97.	2.1	117
70	Decline in neutralising antibody responses, but sustained T cell immunity, in COVID-19 patients at 7 months post-infection. Clinical and Translational Immunology, 2021, 10, e1319.	1.7	34
71	A Meta-Analysis of Rhesus Macaques (<i>Macaca mulatta</i>), Cynomolgus Macaques (<i>Macaca</i>)	0.4	2
72	Post-Mrna Vaccination SARS-CoV-2 IGG Concentrations and Surrogate Virus Neutralization Response Compared by HIV Status and Type of Vaccine: A Matched Case-Control Observational Study. SSRN Electronic Journal, 0, , .	0.4	3
76	COVID-19: Characteristics and Therapeutics. Cells, 2021, 10, 206.	1.8	177
78	SARS-CoV-2 in animals: From potential hosts to animal models. Advances in Virus Research, 2021, 110, 59-102.	0.9	33

#	ARTICLE	IF	CITATIONS
79	Distinct Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals. <i>Frontiers in Immunology</i> , 2020, 11, 618685.	2.2	87
80	A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV-2 in Mice. <i>ACS Central Science</i> , 2021, 7, 183-199.	5.3	134
82	Absence of Vaccine-enhanced Disease With Unexpected Positive Protection Against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by Inactivated Vaccine Given Within 3 Days of Virus Challenge in Syrian Hamster Model. <i>Clinical Infectious Diseases</i> , 2021, 73, e719-e734.	2.9	16
83	Heterogeneity in protocols for bronchoalveolar lavage & sub-genomic RNA evaluation in non-human primate studies of SARS-CoV-2 vaccine candidates' evaluation. <i>Indian Journal of Medical Research</i> , 2021, 153, 702.	0.4	0
86	A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge. <i>Emerging Microbes and Infections</i> , 2021, 10, 1555-1573.	3.0	6
88	Overview of Nonhuman Primate Models of SARS-CoV-2 Infection. <i>Comparative Medicine</i> , 2021, 71, 411-432.	0.4	11
89	The evolutionary dynamics of endemic human coronaviruses. <i>Virus Evolution</i> , 2021, 7, veab020.	2.2	40
91	The 2020 race towards SARS-CoV-2 specific vaccines. <i>Theranostics</i> , 2021, 11, 1690-1702.	4.6	71
92	Review of Covid-19 vaccine clinical trials - A puzzle with missing pieces. <i>International Journal of Biological Sciences</i> , 2021, 17, 1461-1468.	2.6	37
94	SARS-CoV-2 infection and disease outcomes in non-human primate models: advances and implications. <i>Emerging Microbes and Infections</i> , 2021, 10, 1881-1889.	3.0	10
95	Illuminating endosomal escape of polymorphic lipid nanoparticles that boost mRNA delivery. <i>Biomaterials Science</i> , 2021, 9, 4289-4300.	2.6	52
96	mRNA vaccines for COVID-19: what, why and how. <i>International Journal of Biological Sciences</i> , 2021, 17, 1446-1460.	2.6	185
97	SARS-CoV-2: vaccines in the pandemic era. <i>Military Medical Research</i> , 2021, 8, 1.	1.9	104
98	Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans. <i>Vaccines</i> , 2021, 9, 61.	2.1	105
99	Review on Up-to-Date Status of Candidate Vaccines for COVID-19 Disease. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 151-161.	1.1	49
100	Diagnosis, clinical characteristics, and outcomes of COVID-19 patients from a large healthcare system in northern New Jersey. <i>Scientific Reports</i> , 2021, 11, 4389.	1.6	11
101	Comparing COVID-19 vaccine allocation strategies in India: A mathematical modelling study. <i>International Journal of Infectious Diseases</i> , 2021, 103, 431-438.	1.5	178
102	A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2. <i>Nature Communications</i> , 2021, 12, 776.	5.8	65

#	ARTICLE	IF	CITATIONS
103	Point of view on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases. <i>RMD Open</i> , 2021, 7, e001594.	1.8	59
104	Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. <i>Science</i> , 2021, 371, .	6.0	2,268
105	Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. <i>New England Journal of Medicine</i> , 2021, 384, 403-416.	13.9	7,910
106	Development of a coronavirus disease 2019 nonhuman primate model using airborne exposure. <i>PLoS ONE</i> , 2021, 16, e0246366.	1.1	52
108	Acceptance of the COVID-19 vaccine based on the health belief model: A population-based survey in Hong Kong. <i>Vaccine</i> , 2021, 39, 1148-1156.	1.7	363
109	Experimental Models of SARS-CoV-2 Infection: Possible Platforms to Study COVID-19 Pathogenesis and Potential Treatments. <i>Annual Review of Pharmacology and Toxicology</i> , 2022, 62, 25-53.	4.2	20
110	HIV mRNA Vaccinesâ€™ Progress and Future Paths. <i>Vaccines</i> , 2021, 9, 134.	2.1	45
111	COVID-19 mRNA vaccines. <i>Journal of Genetics and Genomics</i> , 2021, 48, 107-114.	1.7	59
112	Early detection of neutralizing antibodies against SARS-CoV-2 in COVID-19 patients in Thailand. <i>PLoS ONE</i> , 2021, 16, e0246864.	1.1	20
113	SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond. <i>Vaccines</i> , 2021, 9, 147.	2.1	175
114	mRNA vaccine: a potential therapeutic strategy. <i>Molecular Cancer</i> , 2021, 20, 33.	7.9	188
115	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. <i>Nature</i> , 2021, 592, 616-622.	13.7	1,232
116	Optimal Allocation of the Limited COVID-19 Vaccine Supply in South Korea. <i>Journal of Clinical Medicine</i> , 2021, 10, 591.	1.0	64
117	Do Corticosteroid Injections for the Treatment of Pain Influence the Efficacy of mRNA COVID-19 Vaccines?. <i>Pain Medicine</i> , 2021, 22, 994-1000.	0.9	7
118	BNT162b vaccines protect rhesus macaques from SARS-CoV-2. <i>Nature</i> , 2021, 592, 283-289.	13.7	494
119	Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines. <i>Pharmaceutics</i> , 2021, 13, 206.	2.0	122
121	In Vitro and In Vivo Models for Studying SARS-CoV-2, the Etiological Agent Responsible for COVID-19 Pandemic. <i>Viruses</i> , 2021, 13, 379.	1.5	53
122	COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform. <i>Vaccines</i> , 2021, 9, 171.	2.1	43

#	ARTICLE	IF	CITATIONS
124	Localized and Systemic Immune Responses against SARS-CoV-2 Following Mucosal Immunization. <i>Vaccines</i> , 2021, 9, 132.	2.1	24
125	Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 48.	7.1	79
126	Synthetic Messenger RNA-Based Vaccines: From Scorn to Hype. <i>Viruses</i> , 2021, 13, 270.	1.5	53
127	Adaptive immunity to SARS-CoV-2 and COVID-19. <i>Cell</i> , 2021, 184, 861-880.	13.5	1,364
128	SARS-CoV-2 virus: Vaccines in development. <i>Fundamental Research</i> , 2021, 1, 131-138.	1.6	12
129	A short discussion about the SARS-CoV-2 mRNA-1273 vaccine. <i>International Journal of Infectious Diseases</i> , 2021, 104, 532-533.	1.5	3
130	Review of studies of severe acute respiratory syndrome related coronavirusâ€™2 pathogenesis in human organoid models. <i>Reviews in Medical Virology</i> , 2021, 31, e2227.	3.9	10
131	Induction of Potent and Durable Neutralizing Antibodies Against SARS-CoV-2 Using a Receptor Binding Domain-Based Immunogen. <i>Frontiers in Immunology</i> , 2021, 12, 637982.	2.2	9
134	Vaccine efficacy probable against COVID-19 variants. <i>Science</i> , 2021, 371, 1116-1116.	6.0	33
136	Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1160-1168.	0.4	38
138	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Challenge Experiments in Nonhuman Primates: An Ethical Perspective. <i>Clinical Infectious Diseases</i> , 2021, 73, 2121-2125.	2.9	1
139	Conformational Changes of the Receptor Binding Domain of SARS-CoV-2 Spike Protein and Prediction of a B-Cell Antigenic Epitope Using Structural Data. <i>Frontiers in Artificial Intelligence</i> , 2021, 4, 630955.	2.0	13
140	Can mRNA Vaccines Turn the Tables During the COVID-19 Pandemic? Current Status and Challenges. <i>Clinical Drug Investigation</i> , 2021, 41, 499-509.	1.1	14
141	Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results. <i>Frontiers in Immunology</i> , 2021, 12, 657711.	2.2	50
142	The Limitless Future of RNA Therapeutics. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 628137.	2.0	296
143	Animal Hosts and Experimental Models of SARS-CoV-2 Infection. <i>Chemotherapy</i> , 2021, 66, 1-9.	0.8	13
144	Why would a Black man volunteer for a government-funded science experiment?. <i>EClinicalMedicine</i> , 2021, 33, 100788.	3.2	0
145	Controlled Human Infection to Speed Up SARS-CoV-2 Vaccine Development. <i>Frontiers in Immunology</i> , 2021, 12, 658783.	2.2	4

#	ARTICLE	IF	CITATIONS
147	COVID-19 vaccines: rapid development, implications, challenges and future prospects. <i>Human Cell</i> , 2021, 34, 711-733.	1.2	227
148	DNA vaccine candidate encoding SARS-CoV-2 spike proteins elicited potent humoral and Th1 cell-mediated immune responses in mice. <i>PLoS ONE</i> , 2021, 16, e0248007.	1.1	32
149	Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques. <i>Nature Communications</i> , 2021, 12, 1386.	5.8	74
150	RNA-based therapies: A cog in the wheel of lung cancer defense. <i>Molecular Cancer</i> , 2021, 20, 54.	7.9	53
152	Immunity to SARS-CoV-2: Lessons Learned. <i>Frontiers in Immunology</i> , 2021, 12, 654165.	2.2	33
153	Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters. <i>Npj Vaccines</i> , 2021, 6, 47.	2.9	43
154	The Importance and Challenges of Identifying SARS-CoV-2 Reinfections. <i>Journal of Clinical Microbiology</i> , 2021, 59, .	1.8	73
155	Case Study: Longitudinal immune profiling of a SARS-CoV-2 reinfection in a solid organ transplant recipient. , 2021, , .		3
156	How to Face the Advent of SARS-CoV-2 Vaccination in IBD Patients: Another Task for Gastroenterologists. <i>Vaccines</i> , 2021, 9, 248.	2.1	0
157	Comparison of Subgenomic and Total RNA in SARS-CoV-2-Challenged Rhesus Macaques. <i>Journal of Virology</i> , 2021, 95, .	1.5	87
159	A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs. <i>Immunity</i> , 2021, 54, 542-556.e9.	6.6	72
160	The Changing Patterns of Consumersâ€™ Behavior in China: A Comparison during and after the COVID-19 Pandemic. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 2447.	1.2	13
161	Soluble Spike DNA Vaccine Provides Long-Term Protective Immunity against SARS-CoV-2 in Mice and Nonhuman Primates. <i>Vaccines</i> , 2021, 9, 307.	2.1	28
162	Does hydroxychloroquine still have any role in the COVID-19 pandemic?. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1257-1266.	0.9	8
163	Current progress and challenges in the design and development of a successful COVID-19 vaccine. <i>Fundamental Research</i> , 2021, 1, 139-150.	1.6	19
164	Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection. <i>Cell</i> , 2021, 184, 1188-1200.e19.	13.5	154
167	Frontrunners in the race to develop a SARS-CoV-2 vaccine. <i>Canadian Journal of Microbiology</i> , 2021, 67, 189-212.	0.8	11
168	COVID-19 vaccines: The status and perspectives in delivery points of view. <i>Advanced Drug Delivery Reviews</i> , 2021, 170, 1-25.	6.6	262

#	ARTICLE	IF	CITATIONS
169	Novel approaches for vaccine development. <i>Cell</i> , 2021, 184, 1589-1603.	13.5	145
170	Nanotechnology, equity and global health. <i>Nature Nanotechnology</i> , 2021, 16, 358-361.	15.6	24
171	Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease. <i>Npj Vaccines</i> , 2021, 6, 39.	2.9	38
173	Nanotechnology for modern medicine: next step towards clinical translation. <i>Journal of Internal Medicine</i> , 2021, 290, 486-498.	2.7	88
174	Response to: COVID-19 reinfection. Vaccinated individuals as a potential source of transmission. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13544.	1.7	8
175	S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates. <i>Nature Communications</i> , 2021, 12, 1346.	5.8	133
176	Advances in gene-based vaccine platforms to address the COVID-19 pandemic. <i>Advanced Drug Delivery Reviews</i> , 2021, 170, 113-141.	6.6	71
177	Precision therapeutic targets for COVID-19. <i>Virology Journal</i> , 2021, 18, 66.	1.4	40
178	The Potential Role of Nonhuman Primate Models to Better Comprehend Early Life Immunity and Maternal Antibody Transfer. <i>Vaccines</i> , 2021, 9, 306.	2.1	3
179	A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development. <i>ACS Central Science</i> , 2021, 7, 512-533.	5.3	217
180	Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans. <i>Science Advances</i> , 2021, 7, .	4.7	100
182	Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. <i>Nature</i> , 2021, 594, 253-258.	13.7	253
183	Seroprevalence of anti-SARS-CoV-2 antibodies in a cohort of New York City metro blood donors using multiple SARS-CoV-2 serological assays: Implications for controlling the epidemic and "Reopening". <i>PLoS ONE</i> , 2021, 16, e0250319.	1.1	14
184	The Mechanism of SARS-CoV-2 Nucleocapsid Protein Recognition by the Human 14-3-3 Proteins. <i>Journal of Molecular Biology</i> , 2021, 433, 166875.	2.0	61
185	The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	347
186	Individually optimal choices can be collectively disastrous in COVID-19 disease control. <i>BMC Public Health</i> , 2021, 21, 832.	1.2	16
189	Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine. <i>ACS Central Science</i> , 2021, 7, 594-602.	5.3	118
190	New Developments and Insights in the Improvement of Mycobacterium tuberculosis Vaccines and Diagnostics Within the End TB Strategy. <i>Current Epidemiology Reports</i> , 2021, 8, 33-45.	1.1	8

#	ARTICLE	IF	CITATIONS
193	Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273. <i>Journal of Pharmacy Practice</i> , 2022, 35, 947-951.	0.5	82
195	Bridging animal and clinical research during SARS-CoV-2 pandemic: A new-old challenge. <i>EBioMedicine</i> , 2021, 66, 103291.	2.7	15
196	Next-Generation COVID-19 Vaccines Should Take Efficiency of Distribution into Consideration. <i>AAPS PharmSciTech</i> , 2021, 22, 126.	1.5	41
200	Positive aspects of the mRNA platform for SARS-CoV-2 vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 2445-2447.	1.4	9
201	Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques. <i>JCI Insight</i> , 2021, 6, .	2.3	52
203	mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents. <i>Npj Vaccines</i> , 2021, 6, 57.	2.9	118
204	Innate and adaptive immune responses toward nanomedicines. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 852-870.	5.7	26
205	N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. <i>Cell</i> , 2021, 184, 2332-2347.e16.	13.5	784
206	Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models. <i>Npj Vaccines</i> , 2021, 6, 61.	2.9	66
207	SARS-CoV-2 vaccines: a triumph of science and collaboration. <i>JCI Insight</i> , 2021, 6, .	2.3	72
208	The Food Anti-Microbials Î²-Phenylethylamine (-HCl) and Ethyl Acetoacetate Do Not Change during the Heating Process. <i>Antibiotics</i> , 2021, 10, 418.	1.5	1
209	Immunogenicity and efficacy of one and two doses of Ad26.COVS.S COVID vaccine in adult and aged NHP. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	55
210	Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma. <i>MBio</i> , 2021, 12, .	1.8	57
211	Status Report on COVID-19 Vaccines Development. <i>Current Infectious Disease Reports</i> , 2021, 23, 9.	1.3	56
212	Protective Efficacy of Inactivated Vaccine against SARS-CoV-2 Infection in Mice and Non-Human Primates. <i>Virologica Sinica</i> , 2021, 36, 879-889.	1.2	17
213	Novel RT-ddPCR assays for measuring the levels of subgenomic and genomic SARS-CoV-2 transcripts. <i>Methods</i> , 2022, 201, 15-25.	1.9	26
214	mRNA therapeutics in cancer immunotherapy. <i>Molecular Cancer</i> , 2021, 20, 69.	7.9	168
215	Progress in research on the S protein as the target of COVID-19 vaccines. <i>Expert Review of Vaccines</i> , 2021, 20, 769-772.	2.0	6

#	ARTICLE	IF	CITATIONS
216	Microarray patches enable the development of skin-targeted vaccines against COVID-19. <i>Advanced Drug Delivery Reviews</i> , 2021, 171, 164-186.	6.6	45
219	Lipid Nanoparticle RBD-hFc mRNA Vaccine Protects hACE2 Transgenic Mice against a Lethal SARS-CoV-2 Infection. <i>Nano Letters</i> , 2021, 21, 4774-4779.	4.5	20
223	Prime-boost vaccination of mice and rhesus macaques with two novel adenovirus vectored COVID-19 vaccine candidates. <i>Emerging Microbes and Infections</i> , 2021, 10, 1002-1015.	3.0	22
224	Characterization of an attenuated SARS-CoV-2 variant with a deletion at the S1/S2 junction of the spike protein. <i>Nature Communications</i> , 2021, 12, 2790.	5.8	26
225	COVID-19 Outcomes in Patients Undergoing B Cell Depletion Therapy and Those with Humoral Immunodeficiency States: A Scoping Review. <i>Pathogens and Immunity</i> , 2021, 6, 76-103.	1.4	56
227	Thermostability, Tunability, and Tenacity of RNA as Rubbery Anionic Polymeric Materials in Nanotechnology and Nanomedicineâ€™ Specific Cancer Targeting with Undetectable Toxicity. <i>Chemical Reviews</i> , 2021, 121, 7398-7467.	23.0	45
228	Frontline Screening for SARS-CoV-2 Infection at Emergency Department Admission by Third Generation Rapid Antigen Test: Can We Spare RT-qPCR?. <i>Viruses</i> , 2021, 13, 818.	1.5	15
230	Safety and antibody response to the first dose of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine in persons with HIV. <i>Aids</i> , 2021, 35, 1872-1874.	1.0	41
231	Interfering with Host Proteases in SARS-CoV-2 Entry as a Promising Therapeutic Strategy. <i>Current Medicinal Chemistry</i> , 2022, 29, 635-665.	1.2	11
232	Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model. <i>Scientific Reports</i> , 2021, 11, 9609.	1.6	46
233	COVID-19 Vaccinated Individuals Can Be a Source of SARS-CoV-2 Transmissionâ€™ A Systematic Review. <i>Hygiene</i> , 2021, 1, 1-11.	0.5	1
235	Polymerase-chain reaction testing to prevent hospital-acquired severe acute respiratory syndrome coronavirus 2 infection in Shinjuku, an epicenter in Tokyo: The Tokyo Women's Medical University model. <i>Respiratory Investigation</i> , 2021, 59, 356-359.	0.9	2
236	SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?. <i>Advanced Drug Delivery Reviews</i> , 2021, 172, 314-338.	6.6	75
237	Tapping the immunological imprints to design chimeric SARS-CoV-2 vaccine for elderly population. <i>International Reviews of Immunology</i> , 2021, , 1-16.	1.5	6
238	Prospective Role of Peptide-Based Antiviral Therapy Against the Main Protease of SARS-CoV-2. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 628585.	1.6	31
240	A Synthetic Peptide CTL Vaccine Targeting Nucleocapsid Confers Protection from SARS-CoV-2 Challenge in Rhesus Macaques. <i>Vaccines</i> , 2021, 9, 520.	2.1	28
242	A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. <i>Vaccine</i> , 2021, 39, 2791-2799.	1.7	185
243	A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 213.	7.1	76

#	ARTICLE	IF	CITATIONS
244	The dawn of mRNA vaccines: The COVID-19 case. <i>Journal of Controlled Release</i> , 2021, 333, 511-520.	4.8	276
245	Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. <i>Npj Vaccines</i> , 2021, 6, 74.	2.9	198
246	Regulatory concepts to guide and promote the accelerated but safe clinical development and licensure of COVID-19 vaccines in Europe. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 72-82.	2.7	11
249	On the road to ending the COVID-19 pandemic: Are we there yet?. <i>Virology</i> , 2021, 557, 70-85.	1.1	38
250	COVID-19 one year into the pandemic: from genetics and genomics to therapy, vaccination, and policy. <i>Human Genomics</i> , 2021, 15, 27.	1.4	39
253	Landscape and selection of vaccine epitopes in SARS-CoV-2. <i>Genome Medicine</i> , 2021, 13, 101.	3.6	30
254	Identification of cross-reactive CD8+ T cell receptors with high functional avidity to a SARS-CoV-2 immunodominant epitope and its natural mutant variants. <i>Genes and Diseases</i> , 2022, 9, 216-229.	1.5	28
255	Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice. <i>Npj Vaccines</i> , 2021, 6, 84.	2.9	52
257	A Comprehensive Overview on the Production of Vaccines in Plant-Based Expression Systems and the Scope of Plant Biotechnology to Combat against SARS-CoV-2 Virus Pandemics. <i>Plants</i> , 2021, 10, 1213.	1.6	15
258	Comparison and Analysis of Neutralizing Antibody Levels in Serum after Inoculating with SARS-CoV-2, MERS-CoV, or SARS-CoV Vaccines in Humans. <i>Vaccines</i> , 2021, 9, 588.	2.1	12
259	Mild SARS-CoV-2 Infections and Neutralizing Antibody Titers. <i>Pediatrics</i> , 2021, 148, .	1.0	44
260	COVID-19 vaccines: Frequently asked questions and updated answers. <i>Infectious Diseases Now</i> , 2021, 51, 319-333.	0.7	10
261	A cautionary perspective regarding the isolation and serial propagation of SARS-CoV-2 in Vero cells. <i>Npj Vaccines</i> , 2021, 6, 83.	2.9	25
262	The Current Status and Challenges in the Development of Vaccines and Drugs against Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2). <i>BioMed Research International</i> , 2021, 2021, 1-20.	0.9	13
263	SARS-CoV-2 vaccines, where do we stand?. <i>Comptes Rendus - Biologies</i> , 2021, 344, 43-55.	0.1	3
264	Updates on the coronavirus disease 2019 vaccine and consideration in children. <i>Clinical and Experimental Pediatrics</i> , 2021, 64, 328-338.	0.9	8
265	SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung. <i>Nature Communications</i> , 2021, 12, 3587.	5.8	71
266	Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?. <i>International Journal of Pharmaceutics</i> , 2021, 603, 120686.	2.6	83

#	ARTICLE	IF	CITATIONS
267	SARS-CoV-2 Subgenomic RNA Kinetics in Longitudinal Clinical Samples. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab310.	0.4	24
268	Low-dose Ad26.COVS.S protection against SARS-CoV-2 challenge in rhesus macaques. <i>Cell</i> , 2021, 184, 3467-3473.e11.	13.5	49
269	SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques. <i>Science Immunology</i> , 2021, 6, .	5.6	34
270	Progression and Trends in Virus from Influenza A to COVID-19: An Overview of Recent Studies. <i>Viruses</i> , 2021, 13, 1145.	1.5	12
271	Infectious disease mRNA vaccines and a review on epitope prediction for vaccine design. <i>Briefings in Functional Genomics</i> , 2021, 20, 289-303.	1.3	16
272	Animal models for SARS-CoV-2. <i>Current Opinion in Virology</i> , 2021, 48, 73-81.	2.6	52
275	Experimental Models for SARS-CoV-2 Infection. <i>Molecules and Cells</i> , 2021, 44, 377-383.	1.0	6
276	Circulating Extracellular Vesicles Carry Immune Regulatory miRNAs and Regulate Vaccine Efficacy and Local Inflammatory Response After Vaccination. <i>Frontiers in Immunology</i> , 2021, 12, 685344.	2.2	13
278	Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	64
280	An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1652-1666.	0.6	38
282	COVID-19 Vaccines: Fabrication Techniques and Current Status. <i>Coronaviruses</i> , 2021, 02, .	0.2	0
283	A yeast-expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates. <i>Science Immunology</i> , 2021, 6, .	5.6	53
284	SARS-CoV-2 spike protein and RNA dependent RNA polymerase as targets for drug and vaccine development: A review. <i>Biosafety and Health</i> , 2021, 3, 249-263.	1.2	16
285	Where to Next? Research Directions after the First Hepatitis C Vaccine Efficacy Trial. <i>Viruses</i> , 2021, 13, 1351.	1.5	1
286	Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques. <i>PLoS Pathogens</i> , 2021, 17, e1009688.	2.1	16
287	Acute encephalitis, myoclonus and Sweet syndrome after mRNA-1273 vaccine. <i>BMJ Case Reports</i> , 2021, 14, e243173.	0.2	46
289	Recent updates on immunological, pharmacological, and alternative approaches to combat COVID-19. <i>Inflammopharmacology</i> , 2021, 29, 1331-1346.	1.9	7
290	Postinfectious Immunity After COVID-19 and Vaccination Against SARS-CoV-2. <i>Viral Immunology</i> , 2021, 34, 504-509.	0.6	5

#	ARTICLE	IF	CITATIONS
291	Functionalized DMP-039 Hybrid Nanoparticle as a Novel mRNA Vector for Efficient Cancer Suicide Gene Therapy. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 5211-5232.	3.3	24
292	Influence of HLA Class II Polymorphism on Predicted Cellular Immunity Against SARS-CoV-2 at the Population and Individual Level. <i>Frontiers in Immunology</i> , 2021, 12, 669357.	2.2	7
294	A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamsters. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	56
295	ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models. <i>Communications Biology</i> , 2021, 4, 915.	2.0	15
297	Maternal Antibody Response, Neutralizing Potency, and Placental Antibody Transfer After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. <i>Obstetrics and Gynecology</i> , 2021, 138, 189-197.	1.2	51
298	Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals. <i>BMC Medicine</i> , 2021, 19, 169.	2.3	52
299	A Machine-Generated View of the Role of Blood Glucose Levels in the Severity of COVID-19. <i>Frontiers in Public Health</i> , 2021, 9, 695139.	1.3	32
300	An Appraisal of the Current Scenario in Vaccine Research for COVID-19. <i>Viruses</i> , 2021, 13, 1397.	1.5	6
302	Detailed Dissection and Critical Evaluation of the Pfizer/BioNTech and Moderna mRNA Vaccines. <i>Vaccines</i> , 2021, 9, 734.	2.1	89
304	Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and Î±OX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity. <i>Frontiers in Immunology</i> , 2021, 12, 719077.	2.2	9
305	Biochemical features and mutations of key proteins in SARS-CoV-2 and their impacts on RNA therapeutics. <i>Biochemical Pharmacology</i> , 2021, 189, 114424.	2.0	27
306	Modification of the Spike Protein for Vaccines against Enveloped RNA Viruses. <i>Molecular Biology</i> , 2021, 55, 538-547.	0.4	2
307	Protection of K18-hACE2 mice and ferrets against SARS-CoV-2 challenge by a single-dose mucosal immunization with a parainfluenza virus 5â€“based COVID-19 vaccine. <i>Science Advances</i> , 2021, 7, .	4.7	60
308	Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	56
309	Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	180
310	Hepatocyte Nuclear Factor 4 alpha 2 Messenger RNA Reprograms Liverâ€“Enriched Transcription Factors and Functional Proteins in Endâ€“Stage Cirrhotic Human Hepatocytes. <i>Hepatology Communications</i> , 2021, 5, 1911-1926.	2.0	7
311	Are We Paving the Way to Dig Out of the â€œPandemic Holeâ€? A Narrative Review on SARS-CoV-2 Vaccination: From Animal Models to Human Immunization. <i>Medical Sciences (Basel, Switzerland)</i> , 2021, 9, 53.	1.3	1
312	COVID-19 Candidate Genes and Pathways Potentially Share the Association with Lung Cancer. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2022, 25, 2463-2472.	0.6	4

#	ARTICLE	IF	CITATIONS
313	Anemia during SARS-CoV-2 infection is associated with rehospitalization after viral clearance. <i>IScience</i> , 2021, 24, 102780.	1.9	4
314	Non-human primate models of human respiratory infections. <i>Molecular Immunology</i> , 2021, 135, 147-164.	1.0	17
316	From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape. <i>Frontiers in Immunology</i> , 2021, 12, 679344.	2.2	74
317	An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages. <i>International Immunopharmacology</i> , 2021, 96, 107763.	1.7	35
318	Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer. <i>JAMA Oncology</i> , 2021, 7, 1507.	3.4	131
319	Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2. <i>Cell Research</i> , 2021, 31, 1011-1023.	5.7	48
321	Vaccine Development against COVID-19: Study from Pre-Clinical Phases to Clinical Trials and Global Use. <i>Vaccines</i> , 2021, 9, 836.	2.1	15
322	Beyond the new normal: Assessing the feasibility of vaccine-based suppression of SARS-CoV-2. <i>PLoS ONE</i> , 2021, 16, e0254734.	1.1	12
323	mRNA-encoded, constitutively active STINGV155M is a potent genetic adjuvant of antigen-specific CD8+ T cell response. <i>Molecular Therapy</i> , 2021, 29, 2227-2238.	3.7	42
324	Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species. <i>Immunity</i> , 2021, 54, 1611-1621.e5.	6.6	190
326	miRNAs; a novel strategy for the treatment of COVID-19. <i>Cell Biology International</i> , 2021, 45, 2045-2053.	1.4	62
327	One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge model. <i>Vaccine</i> , 2021, 39, 4885-4894.	1.7	15
328	A recombinant receptor-binding domain in trimeric form generates protective immunity against SARS-CoV-2 infection in nonhuman primates. <i>Innovation (China)</i> , 2021, 2, 100140.	5.2	19
329	In silico drug repositioning against human NRP1 to block SARS-CoV-2 host entry. <i>Turkish Journal of Biology</i> , 2021, 45, 442-458.	2.1	3
330	Immunity to SARS-CoV-2 induced by infection or vaccination. <i>Journal of Internal Medicine</i> , 2022, 291, 32-50.	2.7	97
331	Lipid Nanoparticles for Broad Spectrum Nucleic Acid Delivery. <i>Advanced Functional Materials</i> , 2021, 31, 2101391.	7.8	13
332	Attenuated activation of pulmonary immune cells in mRNA-1273 vaccinated hamsters after SARS-CoV-2 infection. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	23
333	COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge. <i>Immunity</i> , 2021, 54, 1869-1882.e6.	6.6	59

#	ARTICLE	IF	CITATIONS
334	Role of Potential COVID-19 Immune System Associated Genes and the Potential Pathways Linkage with Type-2 Diabetes. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2022, 25, 2452-2462.	0.6	11
337	COVID-19: The Disease, the Immunological Challenges, the Treatment with Pharmaceuticals and Low-Dose Ionizing Radiation. <i>Cells</i> , 2021, 10, 2212.	1.8	4
338	An Update on mRNA-Based Viral Vaccines. <i>Vaccines</i> , 2021, 9, 965.	2.1	14
339	Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates. <i>Viruses</i> , 2021, 13, 1645.	1.5	8
340	Gaining a better understanding of nonhuman primate research. <i>Science Bulletin</i> , 2021, 66, 1499-1501.	4.3	1
341	Impact of Prior Infection on Severe Acute Respiratory Syndrome Coronavirus 2 Transmission in Syrian Hamsters. <i>Frontiers in Microbiology</i> , 2021, 12, 722178.	1.5	5
342	Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivo. <i>Cell Discovery</i> , 2021, 7, 65.	3.1	51
343	Development of safe and highly protective live-attenuated SARS-CoV-2 vaccine candidates by genome recoding. <i>Cell Reports</i> , 2021, 36, 109493.	2.9	46
344	COVID-19 Research: Lessons from Non-Human Primate Models. <i>Vaccines</i> , 2021, 9, 886.	2.1	15
346	mRNA vaccines for infectious diseases: principles, delivery and clinical translation. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 817-838.	21.5	577
347	mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates. <i>Nature Immunology</i> , 2021, 22, 1306-1315.	7.0	57
348	Antigen Presentation of mRNA-Based and Virus-Vectored SARS-CoV-2 Vaccines. <i>Vaccines</i> , 2021, 9, 848.	2.1	64
349	Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques. <i>Nature Communications</i> , 2021, 12, 5215.	5.8	22
350	B cell depletion in immune-mediated rheumatic diseases and coronavirus disease 2019 (COVID-19). <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 59, 384-393.	0.2	12
351	Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies. <i>Biomedicines</i> , 2021, 9, 1163.	1.4	18
352	Vaccines for COVID-19: A Systematic Review of Feasibility and Effectiveness. <i>Infectious Disorders - Drug Targets</i> , 2022, 22, .	0.4	23
354	A Self-Biomaterialized Novel Adenovirus Vectored COVID-19 Vaccine for Boosting Immunization of Mice. <i>Virologica Sinica</i> , 2021, 36, 1113-1123.	1.2	11
355	Animal experiments show impact of vaccination on reduction of SARS-CoV-2 virus circulation: A model for vaccine development?. <i>Biologicals</i> , 2021, 73, 1-7.	0.5	4

#	ARTICLE	IF	CITATIONS
356	Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2. <i>Science Immunology</i> , 2021, 6, eabl4509.	5.6	141
358	An ultrapotent pan- β -coronavirus lineage B (β -CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope. <i>Protein and Cell</i> , 2022, 13, 655-675.	4.8	25
359	Development of a novel PTD-mediated IVT-mRNA delivery platform for potential protein replacement therapy of metabolic/genetic disorders. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 26, 694-710.	2.3	18
360	Variants of SARS Coronavirus-2 and Their Potential Impact on the Future of the COVID-19 Pandemic. <i>Zoonoses</i> , 2021, 1, .	0.5	3
361	Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques. <i>Science Advances</i> , 2021, 7, eabg7996.	4.7	20
362	Should a third booster dose be scheduled after two doses of CoronaVac? A single-center experience. <i>Journal of Medical Virology</i> , 2022, 94, 287-290.	2.5	34
363	RNA Therapeutics - Research and Clinical Advancements. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 710738.	1.6	39
364	Dual-Antigen COVID-19 Vaccine Subcutaneous Prime Delivery With Oral Boosts Protects NHP Against SARS-CoV-2 Challenge. <i>Frontiers in Immunology</i> , 2021, 12, 729837.	2.2	18
365	Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells. <i>Science</i> , 2021, 374, eabj9853.	6.0	236
366	Nucleic acid delivery and nanoparticle design for COVID vaccines. <i>MRS Bulletin</i> , 2021, 46, 832-839.	1.7	12
367	Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection. <i>Vaccines</i> , 2021, 9, 1017.	2.1	10
369	Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. <i>Science</i> , 2021, 373, eabj0299.	6.0	244
370	Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	44
372	The self-assembled nanoparticle-based trimeric RBD mRNA vaccine elicits robust and durable protective immunity against SARS-CoV-2 in mice. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 340.	7.1	48
374	Blood Analysis of Laboratory <i>Macaca mulatta</i> Used for Neuroscience Research: Investigation of Long-Term and Cumulative Effects of Implants, Fluid Control, and Laboratory Procedures. <i>ENeuro</i> , 2021, 8, ENEURO.0284-21.2021.	0.9	7
375	The development and improvement of ribonucleic acid therapy strategies. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 26, 997-1013.	2.3	11
376	Asunaprevir, a Potent Hepatitis C Virus Protease Inhibitor, Blocks SARS-CoV-2 Propagation. <i>Molecules and Cells</i> , 2021, , .	1.0	3
377	Nanotechnology-empowered vaccine delivery for enhancing CD8+ T cells-mediated cellular immunity. <i>Advanced Drug Delivery Reviews</i> , 2021, 176, 113889.	6.6	48

#	ARTICLE	IF	CITATIONS
378	SARS-CoV-2 Subgenomic RNAs: Characterization, Utility, and Perspectives. <i>Viruses</i> , 2021, 13, 1923.	1.5	38
379	Lipid-nanoparticle-encapsulated mRNA vaccines induce protective memory CD8 T cells against a lethal viral infection. <i>Molecular Therapy</i> , 2021, 29, 2769-2781.	3.7	20
380	An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates. <i>Cell Host and Microbe</i> , 2021, 29, 1437-1453.e8.	5.1	53
381	The First Chemically-Synthesised, Highly Immunogenic Anti-SARS-CoV-2 Peptides in DNA Genotyped Aotus Monkeys for Human Use. <i>Frontiers in Immunology</i> , 2021, 12, 724060.	2.2	5
382	Therapeutic and Protective Potential of Mesenchymal Stem Cells, Pharmaceutical Agents and Current Vaccines Against COVID-19. <i>Current Stem Cell Research and Therapy</i> , 2022, 17, 166-185.	0.6	5
383	Prevention of host-to-host transmission by SARS-CoV-2 vaccines. <i>Lancet Infectious Diseases</i> , The, 2022, 22, e52-e58.	4.6	59
384	Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs. <i>MBio</i> , 2021, 12, e0190821.	1.8	32
385	Vaccinia virus-based vaccines confer protective immunity against SARS-CoV-2 virus in Syrian hamsters. <i>PLoS ONE</i> , 2021, 16, e0257191.	1.1	19
386	Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaques. <i>PLoS Pathogens</i> , 2021, 17, e1009701.	2.1	12
387	Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021. <i>International Immunology</i> , 2021, 33, 529-540.	1.8	28
388	Intradermal-delivered DNA vaccine induces durable immunity mediating a reduction in viral load in a rhesus macaque SARS-CoV-2 challenge model. <i>Cell Reports Medicine</i> , 2021, 2, 100420.	3.3	28
389	COVID-19 Animal Models and Vaccines: Current Landscape and Future Prospects. <i>Vaccines</i> , 2021, 9, 1082.	2.1	8
390	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. <i>Cell</i> , 2021, 184, 5432-5447.e16.	13.5	131
391	Nucleic acid delivery for therapeutic applications. <i>Advanced Drug Delivery Reviews</i> , 2021, 178, 113834.	6.6	122
392	Follicular Helper T Cells in the Immunopathogenesis of SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 2021, 12, 731100.	2.2	32
393	Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects. <i>Microbiology Spectrum</i> , 2021, 9, e0034121.	1.2	114
394	Synthetic modified messenger RNA for therapeutic applications. <i>Acta Biomaterialia</i> , 2021, 131, 1-15.	4.1	34
395	Thrombosis formation after COVID-19 vaccination Immunological Aspects: Review article. <i>Saudi Journal of Biological Sciences</i> , 2022, 29, 1073-1078.	1.8	8

#	ARTICLE	IF	CITATIONS
396	Asunaprevir, a Potent Hepatitis C Virus Protease Inhibitor, Blocks SARS-CoV-2 Propagation. <i>Molecules and Cells</i> , 2021, 44, 688-695.	1.0	11
397	SARS-CoV-2 (Covid-19) vaccines structure, mechanisms and effectiveness: A review. <i>International Journal of Biological Macromolecules</i> , 2021, 188, 740-750.	3.6	83
398	Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2. <i>Biomedicine and Pharmacotherapy</i> , 2021, 142, 111953.	2.5	64
399	SARS-CoV-2 S2P spike ages through distinct states with altered immunogenicity. <i>Journal of Biological Chemistry</i> , 2021, 297, 101127.	1.6	9
400	Exosome-mediated mRNA delivery in vivo is safe and can be used to induce SARS-CoV-2 immunity. <i>Journal of Biological Chemistry</i> , 2021, 297, 101266.	1.6	64
401	Recent advances in detection technologies for COVID-19. <i>Talanta</i> , 2021, 233, 122609.	2.9	12
402	Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1383-1394.	4.6	82
403	Animal models of SARS-CoV-2 and COVID-19 for the development of prophylactic and therapeutic interventions. , 2021, 228, 107931.		18
405	The COVID-19 vaccine: A race nearing the finish line. <i>Apollo Medicine</i> , 2021, .	0.0	1
407	Recombinant chimpanzee adenovirus AdC7 expressing dimeric tandem-repeat spike protein RBD protects mice against COVID-19. <i>Emerging Microbes and Infections</i> , 2021, 10, 1574-1588.	3.0	18
409	Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice. <i>EBioMedicine</i> , 2021, 63, 103197.	2.7	31
410	DNA Nanodevices with Selective Immune Cell Interaction and Function. <i>ACS Nano</i> , 2021, 15, 4394-4404.	7.3	19
411	Current State of the First COVID-19 Vaccines. <i>Vaccines</i> , 2021, 9, 30.	2.1	64
412	Current Status of COVID-19 Vaccine Development: Focusing on Antigen Design and Clinical Trials on Later Stages. <i>Immune Network</i> , 2021, 21, e4.	1.6	26
413	Ongoing Clinical Trials of Vaccines to Fight against COVID-19 Pandemic. <i>Immune Network</i> , 2021, 21, e5.	1.6	21
414	Immunological perspectives on the pathogenesis, diagnosis, prevention and treatment of COVID-19. <i>Molecular Biomedicine</i> , 2021, 2, 1.	1.7	20
415	Potential SARS-CoV-2 Immune Correlates of Protection in Infection and Vaccine Immunization. <i>Pathogens</i> , 2021, 10, 138.	1.2	60
416	Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2. <i>Clinical and Translational Immunology</i> , 2021, 10, e1269.	1.7	45

#	ARTICLE	IF	CITATIONS
417	Advances in vaccination to combat pandemic outbreaks. , 2021, , 123-137.		1
418	Updates on Coronavirus Disease-2019 Vaccine and Consideration in Children. <i>Pediatric Infection and Vaccine</i> , 2021, 28, 7.	0.1	7
420	Nanomaterial Delivery Systems for mRNA Vaccines. <i>Vaccines</i> , 2021, 9, 65.	2.1	310
422	Biomaterials-Based Opportunities to Engineer the Pulmonary Host Immune Response in COVID-19. <i>ACS Biomaterials Science and Engineering</i> , 2021, 7, 1742-1764.	2.6	16
423	Exquisitely Specific anti-KRAS Biodegraders Inform on the Cellular Prevalence of Nucleotide-Loaded States. <i>ACS Central Science</i> , 2021, 7, 274-291.	5.3	46
424	Correlates of protection against SARS-CoV-2 in rhesus macaques. <i>Nature</i> , 2021, 590, 630-634.	13.7	995
425	COVID-19 vaccine development: a pediatric perspective. <i>Current Opinion in Pediatrics</i> , 2021, 33, 144-151.	1.0	76
450	Stages in COVID-19 vaccine development: The Nemesis, the Hubris and the Elpis. <i>International Journal of Clinical Virology</i> , 2020, 4, 126-135.	0.1	7
451	Harnessing Cellular Immunity for Vaccination against Respiratory Viruses. <i>Vaccines</i> , 2020, 8, 783.	2.1	13
452	Comparison of the immunogenicity & protective efficacy of various SARS-CoV-2 vaccine candidates in non-human primates. <i>Indian Journal of Medical Research</i> , 2021, 153, 93.	0.4	28
453	Nanotechnology-based approaches in the fight against SARS-CoV-2. <i>AIMS Microbiology</i> , 2021, 7, 368-398.	1.0	7
454	Heterogeneous Longitudinal Antibody Responses to Covid-19 mRNA Vaccination. <i>BMC Clinical Pathology</i> , 2021, 14, 2632010X2110492.	0.7	9
455	Innovations and development of Covid-19 vaccines: A patent review. <i>Journal of Infection and Public Health</i> , 2022, 15, 123-131.	1.9	27
457	Rational preparation and application of a mRNA delivery system with cytidinyl/cationic lipid. <i>Journal of Controlled Release</i> , 2021, 340, 114-124.	4.8	11
458	The landscape of COVID-19 vaccination among healthcare workers at the first round of COVID-19 vaccination in China: willingness, acceptance and self-reported adverse effects. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 17, 4846-4856.	1.4	7
459	SARS-CoV-2 subunit vaccine adjuvants and their signaling pathways. <i>Expert Review of Vaccines</i> , 2022, 21, 69-81.	2.0	22
460	Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants. <i>Expert Review of Vaccines</i> , 2022, 21, 47-67.	2.0	3
461	Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates. <i>Science</i> , 2021, 374, 1343-1353.	6.0	83

#	ARTICLE	IF	CITATIONS
463	Stabilized coronavirus spike stem elicits a broadly protective antibody. <i>Cell Reports</i> , 2021, 37, 109929.	2.9	64
464	Safety and potency of BIV1â€CovIran inactivated vaccine candidate for SARSâ€CoVâ€2: A preclinical study. <i>Reviews in Medical Virology</i> , 2022, 32, e2305.	3.9	40
465	Airway antibodies emerge according to COVID-19 severity and wane rapidly but reappear after SARS-CoV-2 vaccination. <i>JCI Insight</i> , 2021, 6, .	2.3	27
466	Commercial Interferon-gamma release assay to assess the immune response to first and second doses of mRNA vaccine in previously COVID-19 infected versus uninfected individuals. <i>Diagnostic Microbiology and Infectious Disease</i> , 2022, 102, 115573.	0.8	25
467	Mechanisms of Lung Injury Induced by SARS-CoV-2 Infection. <i>Physiology</i> , 2022, 37, 88-100.	1.6	18
469	Broad-Spectrum and Gram-Negative-Targeting Antibiotics Differentially Regulate Antibody Isotype Responses to Injected Vaccines. <i>Vaccines</i> , 2021, 9, 1240.	2.1	3
470	Acute Corneal Transplant Rejection After COVID-19 Vaccination. <i>Cornea</i> , 2022, 41, 121-124.	0.9	26
472	Recent Update of COVID-19 Vaccines. <i>Advanced Pharmaceutical Bulletin</i> , 2021, , .	0.6	0
473	Ultrasonic particles: An approach for targeted gene delivery. <i>Advanced Drug Delivery Reviews</i> , 2021, 179, 113998.	6.6	20
474	A practical approach to SARS-CoV-2 testing in a pre and post-vaccination era. <i>Journal of Clinical Virology Plus</i> , 2021, 1, 100044.	0.4	2
475	What Happens to the Immune System after Vaccination or Recovery from COVID-19?. <i>Life</i> , 2021, 11, 1152.	1.1	5
476	Longitudinal Immune Profiling of a Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection in a Solid Organ Transplant Recipient. <i>Journal of Infectious Diseases</i> , 2022, 225, 374-384.	1.9	7
477	Glycosylation and Serological Reactivity of an Expression-enhanced SARS-CoV-2 Viral Spike Mimetic. <i>Journal of Molecular Biology</i> , 2022, 434, 167332.	2.0	22
478	Complete protection by a single-dose skin patchâ€ delivered SARS-CoV-2 spike vaccine. <i>Science Advances</i> , 2021, 7, eabj8065.	4.7	31
479	A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge. <i>Npj Vaccines</i> , 2021, 6, 129.	2.9	47
480	Scientific rationale for developing potent RBD-based vaccines targeting COVID-19. <i>Npj Vaccines</i> , 2021, 6, 128.	2.9	102
488	Dynamics of SARS-CoV-2 variants of concern (VOC) in Bangladesh during the first half of 2021. <i>Virology</i> , 2022, 565, 29-37.	1.1	7
489	The nano delivery systems and applications of mRNA. <i>European Journal of Medicinal Chemistry</i> , 2022, 227, 113910.	2.6	52

#	ARTICLE	IF	CITATIONS
492	Vaccine-Induced Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and the Path to Accelerating Development (Determining a Correlate of Protection). <i>Clinics in Laboratory Medicine</i> , 2022, 42, 111-128.	0.7	8
493	Immunopathology and Immunopathogenesis of COVID-19, what we know and what we should learn. <i>Gene Reports</i> , 2021, 25, 101417.	0.4	15
494	Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. <i>Immunity</i> , 2021, 54, 2877-2892.e7.	6.6	260
495	Appendicitis as a possible safety signal for the COVID-19 vaccines. <i>Vaccine: X</i> , 2021, 9, 100122.	0.9	14
496	An Established Th2-Oriented Response to an Alum-Adjuvanted SARS-CoV-2 Subunit Vaccine Is Not Reversible by Sequential Immunization with Nucleic Acid-Adjuvanted Th1-Oriented Subunit Vaccines. <i>Vaccines</i> , 2021, 9, 1261.	2.1	10
497	Career advice from my father: "Go where you are loved". <i>Molecular Biology of the Cell</i> , 2021, 32, ae3.	0.9	0
501	Efficacy and safety of potential vaccine candidates against coronavirus disease 2019: A systematic review. <i>Journal of Advanced Pharmaceutical Technology and Research</i> , 2021, 12, 215-221.	0.4	2
502	Poor Antibody Response to BioNTech/Pfizer Coronavirus Disease 2019 Vaccination in Severe Acute Respiratory Syndrome Coronavirus 2 "Naive Residents of Nursing Homes. <i>Clinical Infectious Diseases</i> , 2022, 75, e695-e704.	2.9	23
503	Innovative recombinant protein-based vaccines against SARS-CoV-2. , 2022, , 193-211.		1
504	RNA-based vaccines against SARS-CoV-2. , 2022, , 129-152.		1
505	T helper type (Th1/Th2) responses to SARS-CoV-2 and influenza A (H1N1) virus: From cytokines produced to immune responses. <i>Transplant Immunology</i> , 2022, 70, 101495.	0.6	58
506	A Pervasive Review on New Advancements of Nano Vaccines on Covid-19 Pandemic. <i>International Journal of Pharmaceutical Sciences Review and Research</i> , 2021, 70, .	0.1	1
508	SARS-CoV-2 Infection of Rhesus Macaques Treated Early with Human COVID-19 Convalescent Plasma. <i>Microbiology Spectrum</i> , 2021, 9, e0139721.	1.2	15
509	Analysis of Glycosylation and Disulfide Bonding of Wild-Type SARS-CoV-2 Spike Glycoprotein. <i>Journal of Virology</i> , 2022, 96, JVI0162621.	1.5	24
510	PD-1 blockade counteracts post-COVID-19 immune abnormalities and stimulates the anti-SARS-CoV-2 immune response. <i>JCI Insight</i> , 2021, 6, .	2.3	51
511	The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview. <i>Vaccines</i> , 2021, 9, 1345.	2.1	22
512	Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine. <i>Nature</i> , 2022, 601, 410-414.	13.7	71
513	Are COVID-19 Vaccine Boosters Needed? The Science behind Boosters. <i>Journal of Virology</i> , 2022, 96, JVI0197321.	1.5	35

#	ARTICLE	IF	CITATIONS
514	Comments on Thrombosis After Vaccination: The Leader Sequence of the Spike Protein Might Be Responsible for Thrombosis and Antibody-Mediated Thrombocytopenia. <i>Viral Immunology</i> , 2021, , .	0.6	1
515	A two-adjuvant multiantigen candidate vaccine induces superior protective immune responses against SARS-CoV-2 challenge. <i>Cell Reports</i> , 2021, 37, 110112.	2.9	22
516	The glycosylation in SARS-CoV-2 and its receptor ACE2. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 396.	7.1	111
517	Bioengineering Strategies for Developing Vaccines against Respiratory Viral Diseases. <i>Clinical Microbiology Reviews</i> , 2022, 35, e0012321.	5.7	10
518	Pneumococcal Vaccines: Past Findings, Present Work, and Future Strategies. <i>Vaccines</i> , 2021, 9, 1338.	2.1	17
519	Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges. <i>Biomedicines</i> , 2021, 9, 1740.	1.4	16
520	Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity. <i>Seminars in Immunology</i> , 2021, 55, 101533.	2.7	72
521	Nucleoside-Modified mRNA Vaccines Protect IFNAR ¹ Mice against Crimean-Congo Hemorrhagic Fever Virus Infection. <i>Journal of Virology</i> , 2022, 96, JVI0156821.	1.5	24
522	Covid-19 vaccines and variants of concern: A review. <i>Reviews in Medical Virology</i> , 2022, 32, e2313.	3.9	201
523	Modulating intracellular pathways to improve non-viral delivery of RNA therapeutics. <i>Advanced Drug Delivery Reviews</i> , 2022, 181, 114041.	6.6	26
525	Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung. <i>Cell</i> , 2022, 185, 113-130.e15.	13.5	64
526	Prediction of lipid nanoparticles for mRNA vaccines by the machine learning algorithm. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 2950-2962.	5.7	33
527	Predicting infectivity: comparing four PCR-based assays to detect culturable SARS-CoV-2 in clinical samples. <i>EMBO Molecular Medicine</i> , 2022, 14, e15290.	3.3	38
528	Temporal variations in country-specific mutational profiles of SARS-CoV-2: effect on vaccine efficacy. <i>Future Virology</i> , 2021, 16, 805-819.	0.9	2
529	High DNA-Binding Affinity and Gene-Transfection Efficacy of Bioreducible Cationic Nanomicelles. <i>Biomaterial Engineering</i> , 2021, , 1-15.	0.1	0
530	mRNA Vaccine: An Advanced and Transformative Technology for Vaccine Development. , 2021, , 273-287.		0
532	Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies. <i>Nanoscale</i> , 2022, 14, 1054-1074.	2.8	22
533	Optimization of Single-Dose VSV-Based COVID-19 Vaccination in Hamsters. <i>Frontiers in Immunology</i> , 2021, 12, 788235.	2.2	11

#	ARTICLE	IF	CITATIONS
534	Nanoscale self-assembly: concepts, applications and challenges. <i>Nanotechnology</i> , 2022, 33, 132001.	1.3	32
535	Assessment of the efficacy of SARS-CoV-2 vaccines in non-human primate studies: a systematic review. <i>Open Research Europe</i> , 0, 2, 4.	2.0	0
536	Animal models in vaccinology: state of the art and future perspectives for an animal-free approach. <i>Current Opinion in Microbiology</i> , 2022, 66, 46-55.	2.3	1
537	Intranasal HD-Ad vaccine protects the upper and lower respiratory tracts of hACE2 mice against SARS-CoV-2. <i>Cell and Bioscience</i> , 2021, 11, 202.	2.1	13
538	Extended interval BNT162b2 vaccination enhances peak antibody generation. <i>Npj Vaccines</i> , 2022, 7, 14.	2.9	101
541	DNA Based Vaccine Expressing SARS-CoV-2 Spike-CD40L Fusion Protein Confers Protection Against Challenge in a Syrian Hamster Model. <i>Frontiers in Immunology</i> , 2021, 12, 785349.	2.2	7
542	Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines. <i>Pharmacological Reviews</i> , 2022, 74, 313-339.	7.1	9
543	From Bench to the Clinic: The Path to Translation of Nanotechnology-Enabled mRNA SARS-CoV-2 Vaccines. <i>Nano-Micro Letters</i> , 2022, 14, 41.	14.4	26
544	Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination in mouse models. <i>EBioMedicine</i> , 2022, 75, 103762.	2.7	32
545	Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection. <i>Cell Reports Medicine</i> , 2022, 3, 100528.	3.3	6
546	A new testing platform using fingerstick blood for quantitative antibody response evaluation after SARS-CoV-2 vaccination. <i>Emerging Microbes and Infections</i> , 2022, 11, 250-259.	3.0	3
547	A Polylactide-Based Micellar Adjuvant Improves the Intensity and Quality of Immune Response. <i>Pharmaceutics</i> , 2022, 14, 107.	2.0	3
548	Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B. <i>Science Advances</i> , 2022, 8, eabj9815.	4.7	29
549	Plant-Based Vaccines in Combat against Coronavirus Diseases. <i>Vaccines</i> , 2022, 10, 138.	2.1	13
550	Effectiveness of and Immune Responses to SARS-CoV-2 mRNA Vaccines and Their Mechanisms. <i>Journal of Disaster Research</i> , 2022, 17, 7-20.	0.4	2
551	Higher Proinflammatory Cytokines Are Associated With Increased Antibody Titer After a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients. <i>Transplantation</i> , 2022, 106, 835-841.	0.5	15
553	mRNA Vaccines in the COVID-19 Pandemic and Beyond. <i>Annual Review of Medicine</i> , 2022, 73, 17-39.	5.0	120
554	Rapid Protection from COVID-19 in Nonhuman Primates Vaccinated Intramuscularly but Not Intranasally with a Single Dose of a Vesicular Stomatitis Virus-Based Vaccine. <i>MBio</i> , 2022, 13, e0337921.	1.8	18

#	ARTICLE	IF	CITATIONS
555	Advances and gaps in SARS-CoV-2 infection models. <i>PLoS Pathogens</i> , 2022, 18, e1010161.	2.1	61
556	In-vitro and In-vivo Experimental Models for MERS-CoV, SARS-CoV and SARS-CoV-2 Viral Infection: A Compendious Review. <i>Recent Patents on Biotechnology</i> , 2022, 16, .	0.4	1
557	Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates. <i>Npj Vaccines</i> , 2022, 7, 7.	2.9	35
558	Coronavirus Disease 2019 Messenger RNA Vaccines Associated With Delayed Onset of Breakthrough Infections and Fewer Radiographic Abnormalities. <i>Clinical Infectious Diseases</i> , 2022, 75, e905-e908.	2.9	5
559	Identification and Tracking of Alloreactive T Cell Clones in Rhesus Macaques Through the RM-scTCR-Seq Platform. <i>Frontiers in Immunology</i> , 2021, 12, 804932.	2.2	7
560	An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	57
561	Ulcers on the bilateral palate mucosa following mRNA-based vaccination for coronavirus disease 2019 (COVID-19): A case report. <i>Journal of Stomatology, Oral and Maxillofacial Surgery</i> , 2022, 123, 283-286.	0.5	7
563	Modulation of immunosuppressant drug treatment to improve SARS-CoV-2 vaccine efficacy in mice. <i>Vaccine</i> , 2022, 40, 854-861.	1.7	5
564	Comparison of immune responses induced by two or three doses of an alum α adjuvanted inactivated SARS α CoV α 2 vaccine in mice. <i>Journal of Medical Virology</i> , 2022, , .	2.5	4
565	A comprehensive review on COVID-19 vaccines: development, effectiveness, adverse effects, distribution and challenges. <i>VirusDisease</i> , 2022, 33, 1-22.	1.0	47
566	A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques. <i>Med</i> , 2022, 3, 188-203.e4.	2.2	11
567	A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report. <i>Vaccine</i> , 2022, 40, 2044-2052.	1.7	11
568	In silico analysis of mutant epitopes in new SARS-CoV-2 lineages suggest global enhanced CD8+ T cell reactivity and also signs of immune response escape. <i>Infection, Genetics and Evolution</i> , 2022, 99, 105236.	1.0	6
569	An adjuvant strategy enabled by modulation of the physical properties of microbial ligands expands antigen immunogenicity. <i>Cell</i> , 2022, 185, 614-629.e21.	13.5	40
571	The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-20.	1.4	163
572	Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in mice. <i>Npj Vaccines</i> , 2022, 7, 17.	2.9	19
573	Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2 α experienced individuals. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	65
574	Nanobiotechnology approaches for cardiovascular diseases: site-specific targeting of drugs and nanoparticles for atherothrombosis. <i>Journal of Nanobiotechnology</i> , 2022, 20, 75.	4.2	11

#	ARTICLE	IF	CITATIONS
575	Toward finding the difference between untreated celiac disease and COVID-19 infected patients in terms of CD4, CD25 (IL-2 R α), FOXP3 and IL-6 expressions as genes affecting immune homeostasis. <i>BMC Gastroenterology</i> , 2021, 21, 462.	0.8	7
576	A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques. <i>Nature Medicine</i> , 2021, 27, 2234-2245.	15.2	80
577	A single intranasal dose of a live-attenuated parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in hamsters. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	43
578	Differences in Post-mRNA Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunoglobulin G (IgG) Concentrations and Surrogate Virus Neutralization Test Response by Human Immunodeficiency Virus (HIV) Status and Type of Vaccine: A Matched Case-Control Observational Study. <i>Clinical Infectious Diseases</i> , 2022, 75, e916-e919.	2.9	42
582	Chimeric Fusion (F) and Attachment (G) Glycoprotein Antigen Delivery by mRNA as a Candidate Nipah Vaccine. <i>Frontiers in Immunology</i> , 2021, 12, 772864.	2.2	21
585	An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor-binding domain vaccine in aged mice. <i>Science Translational Medicine</i> , 2021, , eabj5305.	5.8	4
586	Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2 experienced individuals. <i>Science Translational Medicine</i> , 2021, , eabi8961.	5.8	22
587	Long-term stability and protection efficacy of the RBD-targeting COVID-19 mRNA vaccine in nonhuman primates. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 438.	7.1	29
588	Human Challenge Studies with Coronaviruses Old and New. <i>Current Topics in Microbiology and Immunology</i> , 2021, , 1.	0.7	0
589	Evaluation of Peppermint Leaf Flavonoids as SARS-CoV-2 Spike Receptor-Binding Domain Attachment Inhibitors to the Human ACE2 Receptor: A Molecular Docking Study. <i>Open Journal of Biophysics</i> , 2022, 12, 132-152.	0.7	3
590	Biotechnology strategies for the development of novel therapeutics and vaccines against the novel COVID-19 pandemic. , 2022, , 205-226.		0
592	Durability and expansion of neutralizing antibody breadth following Ad26.COVS.S vaccination of mice. <i>Npj Vaccines</i> , 2022, 7, 23.	2.9	6
593	Performance evaluation of an automatic chemiluminescence immune platform for SARS-CoV-2 neutralizing antibody after vaccination in real world. <i>BMC Infectious Diseases</i> , 2022, 22, 157.	1.3	2
594	Vaccine Candidate Against COVID-19 Based on Structurally Modified Plant Virus as an Adjuvant. <i>Frontiers in Microbiology</i> , 2022, 13, 845316.	1.5	8
595	Immune Escape Mechanism and Vaccine Research Progress of African Swine Fever Virus. <i>Vaccines</i> , 2022, 10, 344.	2.1	23
596	A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	73
597	Identification of a Potential mRNA-based Vaccine Candidate against the SARS-CoV-2 Spike Glycoprotein: A Reverse Vaccinology Approach. <i>ChemistrySelect</i> , 2022, 7, .	0.7	9
598	SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern. <i>ELife</i> , 2022, 11, .	2.8	26

#	ARTICLE	IF	CITATIONS
599	Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics. <i>Pharmaceutics</i> , 2022, 14, 398.	2.0	31
602	Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates. <i>Nature Communications</i> , 2022, 13, 1699.	5.8	34
603	Multiple SARS-CoV-2 Variants Exhibit Variable Target Cell Infectivity and Ability to Evade Antibody Neutralization. <i>Frontiers in Immunology</i> , 2022, 13, 836232.	2.2	15
604	Characterization of immune responses in fully vaccinated individuals after breakthrough infection with the SARS-CoV-2 delta variant. <i>Science Translational Medicine</i> , 2022, 14, eabn6150.	5.8	57
605	Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults. <i>Nature Medicine</i> , 2022, 28, 1031-1041.	15.2	281
606	Current Status and Future Perspectives on mRNA Drug Manufacturing. <i>Molecular Pharmaceutics</i> , 2022, 19, 1047-1058.	2.3	44
607	Messenger RNA vaccines for cancer immunotherapy: progress promotes promise. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	27
610	A bacterial extracellular vesicle-based intranasal vaccine against SARS-CoV-2 protects against disease and elicits neutralizing antibodies to wild-type and Delta variants. <i>Journal of Extracellular Vesicles</i> , 2022, 11, e12192.	5.5	60
611	Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2. <i>PeerJ</i> , 2022, 10, e13083.	0.9	14
612	A 1-year longitudinal study on COVID-19 convalescents reveals persistence of anti-SARS-CoV-2 humoral and cellular immunity. <i>Emerging Microbes and Infections</i> , 2022, 11, 902-913.	3.0	7
613	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. <i>Cell</i> , 2022, 185, 1556-1571.e18.	13.5	179
615	Biotechnological Perspectives to Combat the COVID-19 Pandemic: Precise Diagnostics and Inevitable Vaccine Paradigms. <i>Cells</i> , 2022, 11, 1182.	1.8	10
616	Insights From Early Clinical Trials Assessing Response to mRNA SARS-CoV-2 Vaccination in Immunocompromised Patients. <i>Frontiers in Immunology</i> , 2022, 13, 827242.	2.2	5
617	A modified vaccinia Ankara vaccine expressing spike and nucleocapsid protects rhesus macaques against SARS-CoV-2 Delta infection. <i>Science Immunology</i> , 2022, 7, eabo0226.	5.6	22
618	A Review of SARS-CoV-2 Disease (COVID-19): Pandemic in Our Time. <i>Pathogens</i> , 2022, 11, 368.	1.2	23
619	Novel Assays for Molecular Detection of Severe Acute Respiratory Syndrome Coronavirus 2. <i>Clinics in Laboratory Medicine</i> , 2022, 42, 299-307.	0.7	2
620	mRNA vaccination in octogenarians 15 and 20 months after recovery from COVID-19 elicits robust immune and antibody responses that include Omicron. <i>Cell Reports</i> , 2022, 39, 110680.	2.9	21
621	Anthropogenic effects on body size and growth in lab-reared and free-ranging <i>Macaca mulatta</i> . <i>American Journal of Primatology</i> , 2022, 84, e23368.	0.8	0

#	ARTICLE	IF	CITATIONS
622	Mild SARS-CoV-2 infection in rhesus macaques is associated with viral control prior to antigen-specific T cell responses in tissues. <i>Science Immunology</i> , 2022, 7, eabo0535.	5.6	17
623	IMGT [®] Biocuration and Analysis of the Rhesus Monkey IG Loci. <i>Vaccines</i> , 2022, 10, 394.	2.1	3
624	Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong. <i>EBioMedicine</i> , 2022, 77, 103904.	2.7	93
625	Circular RNA vaccines against SARS-CoV-2 and emerging variants. <i>Cell</i> , 2022, 185, 1728-1744.e16.	13.5	211
626	Development of COVID 19 vaccine: A summarized review on global trials, efficacy, and effectiveness on variants. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2022, 16, 102482.	1.8	9
628	Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates. <i>Vaccine</i> , 2022, 40, 2960-2969.	1.7	5
629	Th2-Oriented Immune Serum After SARS-CoV-2 Vaccination Does Not Enhance Infection In Vitro. <i>Frontiers in Immunology</i> , 2022, 13, 882856.	2.2	4
630	Application of pseudovirus system in the development of vaccine, antiviral-drugs, and neutralizing antibodies. <i>Microbiological Research</i> , 2022, 258, 126993.	2.5	22
631	mRNA vaccines for COVID-19 and diverse diseases. <i>Journal of Controlled Release</i> , 2022, 345, 314-333.	4.8	50
632	SARS-CoV-2 infections in mRNA vaccinated individuals are biased for viruses encoding spike E484K and associated with reduced infectious virus loads that correlate with respiratory antiviral IgG levels. <i>Journal of Clinical Virology</i> , 2022, 150-151, 105151.	1.6	11
633	Development of an In Vivo Probe to Track SARS-CoV-2 Infection in Rhesus Macaques. <i>Frontiers in Immunology</i> , 2021, 12, 810047.	2.2	3
634	Molecular and Clinical Aspects of COVID-19 Vaccines and Other Therapeutic Interventions Apropos Emerging Variants of Concern. <i>Frontiers in Pharmacology</i> , 2021, 12, 778219.	1.6	0
636	Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2. <i>Npj Vaccines</i> , 2021, 6, 156.	2.9	15
638	Propagation of SARS-CoV-2 in Calu-3 Cells to Eliminate Mutations in the Furin Cleavage Site of Spike. <i>Viruses</i> , 2021, 13, 2434.	1.5	19
640	COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review. <i>3 Biotech</i> , 2022, 12, 15.	1.1	20
642	Advances in the design and development of SARS-CoV-2 vaccines. <i>Military Medical Research</i> , 2021, 8, 67.	1.9	26
644	Phosphate-mediated coanchoring of RBD immunogens and molecular adjuvants to alum potentiates humoral immunity against SARS-CoV-2. <i>Science Advances</i> , 2021, 7, eabj6538.	4.7	19
645	State-of-the-art preclinical evaluation of COVID-19 vaccine candidates. <i>Exploration of Immunology</i> , 0, , 440-460.	1.7	0

#	ARTICLE	IF	CITATIONS
646	Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together. <i>Frontiers in Immunology</i> , 2021, 12, 790469.	2.2	15
647	Techniques for Developing and Assessing Immune Responses Induced by Synthetic DNA Vaccines for Emerging Infectious Diseases. <i>Methods in Molecular Biology</i> , 2022, 2410, 229-263.	0.4	1
648	Modified mRNA-Based Vaccines Against Coronavirus Disease 2019. <i>Cell Transplantation</i> , 2022, 31, 096368972210902.	1.2	3
649	Surveillance and Correlation of Severe Acute Respiratory Syndrome Coronavirus 2 Viral RNA, Antigen, Virus Isolation, and Self-Reported Symptoms in a Longitudinal Study With Daily Sampling. <i>Clinical Infectious Diseases</i> , 2022, 75, 1698-1705.	2.9	8
650	A Capsid Virus-Like Particle-Based SARS-CoV-2 Vaccine Induces High Levels of Antibodies and Protects Rhesus Macaques. <i>Frontiers in Immunology</i> , 2022, 13, 857440.	2.2	15
651	Ad26.COVS.S prevents upregulation of SARS-CoV-2 induced pathways of inflammation and thrombosis in hamsters and rhesus macaques. <i>PLoS Pathogens</i> , 2022, 18, e1009990.	2.1	4
652	A Highly Potent SARS-CoV-2 Blocking Lectin Protein. <i>ACS Infectious Diseases</i> , 2022, 8, 1253-1264.	1.8	20
653	Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease. <i>Journal of Virology</i> , 2022, 96, e0038922.	1.5	5
654	Development of antibody resistance in emerging mutant strains of SARS CoV-2: Impediment for COVID-19 vaccines. <i>Reviews in Medical Virology</i> , 2022, 32, e2346.	3.9	16
655	A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity. <i>Molecular Therapy</i> , 2022, 30, 2968-2983.	3.7	20
656	COVID-19 Vaccines: Current and Future Perspectives. <i>Vaccines</i> , 2022, 10, 608.	2.1	26
657	Detailed analysis of antibody responses to SARS-CoV-2 vaccination and infection in macaques. <i>PLoS Pathogens</i> , 2022, 18, e1010155.	2.1	6
658	Cross-reactive antibodies elicited to conserved epitopes on SARS-CoV-2 spike protein after infection and vaccination. <i>Scientific Reports</i> , 2022, 12, 6496.	1.6	20
659	Artificial neural network-based estimation of COVID-19 case numbers and effective reproduction rate using wastewater-based epidemiology. <i>Water Research</i> , 2022, 218, 118451.	5.3	52
660	Advances in COVID-19 mRNA vaccine development. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 94.	7.1	177
661	Ethical Issues involving the development of Covid-19 vaccines: Role of vaccine development, clinical trials and speed of peer review in dissuading public vaccine hesitancy. <i>Ethics in Biology, Engineering & Medicine</i> , 2022, , .	0.1	0
662	High DNA-Binding Affinity and Gene-Transfection Efficacy of Bioreducible Cationic Nanomicelles. <i>Biomaterial Engineering</i> , 2022, , 293-307.	0.1	0
663	Considerations for the Feasibility of Neutralizing Antibodies as a Surrogate Endpoint for COVID-19 Vaccines. <i>Frontiers in Immunology</i> , 2022, 13, 814365.	2.2	10

#	ARTICLE	IF	CITATIONS
664	Nanoparticles for Coronavirus Control. <i>Nanomaterials</i> , 2022, 12, 1602.	1.9	9
665	Recent developments in SARS-CoV-2 vaccines: A systematic review of the current studies. <i>Reviews in Medical Virology</i> , 2023, 33, e2359.	3.9	17
666	A SARS-CoV-2 Spike Ferritin Nanoparticle Vaccine Is Protective and Promotes a Strong Immunological Response in the Cynomolgus Macaque Coronavirus Disease 2019 (COVID-19) Model. <i>Vaccines</i> , 2022, 10, 717.	2.1	15
667	In vivo fate and intracellular trafficking of vaccine delivery systems. <i>Advanced Drug Delivery Reviews</i> , 2022, 186, 114325.	6.6	26
668	COVID-19 Vaccines and the Efficacy of Currently Available Vaccines Against COVID-19 Variants. <i>Cureus</i> , 2022, , .	0.2	3
669	Toll-like receptor-agonist-based therapies for respiratory viral diseases: thinking outside the cell. <i>European Respiratory Review</i> , 2022, 31, 210274.	3.0	9
670	TEAD4 as an Oncogene and a Mitochondrial Modulator. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	1.8	7
671	COVID-19 vaccine development: milestones, lessons and prospects. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 146.	7.1	153
672	nSARS-CoV-2 and COVID-19 Pandemic: From Emergence to Vaccination. <i>Dr Sulaiman Al Habib Medical Journal</i> , 0, , 1.	0.3	0
673	Vaccines for Covid-19: An insight on their effectiveness and adverse effects. <i>Journal of Medical Virology</i> , 2022, , .	2.5	7
674	BCG-Based Vaccines Elicit Antigen-Specific Adaptive and Trained Immunity against SARS-CoV-2 and Andes orthohantavirus. <i>Vaccines</i> , 2022, 10, 721.	2.1	12
675	Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice. <i>Npj Vaccines</i> , 2022, 7, .	2.9	32
676	Development of an LNP-Encapsulated mRNA-RBD Vaccine against SARS-CoV-2 and Its Variants. <i>Pharmaceutics</i> , 2022, 14, 1101.	2.0	15
677	Animal models for studying coronavirus infections and developing antiviral agents and vaccines. <i>Antiviral Research</i> , 2022, 203, 105345.	1.9	7
678	Analysis of SARS-CoV-2 known and novel subgenomic mRNAs in cell culture, animal model, and clinical samples using LeTRS, a bioinformatic tool to identify unique sequence identifiers. <i>GigaScience</i> , 2022, 11, .	3.3	8
679	Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients – implications for the omicron variant. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 1417-1425.	0.3	10
680	Humoral and cellular immune memory to four COVID-19 vaccines. <i>Cell</i> , 2022, 185, 2434-2451.e17.	13.5	289
681	mRNA-based therapeutics: powerful and versatile tools to combat diseases. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	160

#	ARTICLE	IF	CITATIONS
683	Characterization of Immune Response Diversity in Rodents Vaccinated with a Vesicular Stomatitis Virus Vectored COVID-19 Vaccine. <i>Viruses</i> , 2022, 14, 1127.	1.5	7
684	Protective neutralizing epitopes in SARS-CoV-2. <i>Immunological Reviews</i> , 2022, 310, 76-92.	2.8	23
685	Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron. <i>PLoS ONE</i> , 2022, 17, e0268767.	1.1	18
687	Principles of SARS-CoV-2 glycosylation. <i>Current Opinion in Structural Biology</i> , 2022, 75, 102402.	2.6	27
688	Nonhuman primate models for evaluation of SARS-CoV-2 vaccines. <i>Expert Review of Vaccines</i> , 2022, 21, 1055-1070.	2.0	1
689	Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. <i>Immunological Reviews</i> , 2022, 310, 6-26.	2.8	138
690	mRNA-1273 vaccination protects against SARS-CoV-2-elicited lung inflammation in nonhuman primates. <i>JCI Insight</i> , 2022, 7, .	2.3	3
691	Advances in Circular RNA and Its Applications. <i>International Journal of Medical Sciences</i> , 2022, 19, 975-985.	1.1	46
692	Advances in mRNA vaccines. <i>International Review of Cell and Molecular Biology</i> , 2022, , 295-316.	1.6	9
693	Exploring the myths surrounding the COVID-19 vaccines in Africa: the study to investigate their impacts on acceptance using online survey and social media. <i>Clinical and Experimental Vaccine Research</i> , 2022, 11, 193.	1.1	5
694	An intranasally administrated SARS-CoV-2 beta variant subunit booster vaccine prevents beta variant replication in rhesus macaques. , 2022, 1, .		10
695	Low-dose self-amplifying mRNA COVID-19 vaccine drives strong protective immunity in non-human primates against SARS-CoV-2 infection. <i>Nature Communications</i> , 2022, 13, .	5.8	28
696	Systemic Neutralizing Antibodies and Local Immune Responses Are Critical for the Control of SARS-CoV-2. <i>Viruses</i> , 2022, 14, 1262.	1.5	1
697	Coronavirus Disease 2019 Vaccinations in Patients With Chronic Liver Disease and Liver Transplant Recipients: An Update. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	8
699	Immunological memory to SARS-CoV-2 infection and COVID-19 vaccines. <i>Immunological Reviews</i> , 2022, 310, 27-46.	2.8	137
700	A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273). <i>Vaccine</i> , 2022, 40, 5275-5293.	1.7	3
701	SARS-CoV-2 Whole-Genome Sequencing by Ion S5 Technology—Challenges, Protocol Optimization and Success Rates for Different Strains. <i>Viruses</i> , 2022, 14, 1230.	1.5	0
702	A Review on DNA Vaccines in Pre-Clinical Trials Against SARS-CoV-2. <i>Journal of Experimental Biology and Agricultural Sciences</i> , 2022, 10, 487-493.	0.1	4

#	ARTICLE	IF	CITATIONS
703	Cell and Animal Models for SARS-CoV-2 Research. <i>Viruses</i> , 2022, 14, 1507.	1.5	9
704	Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection. <i>ELife</i> , 0, 11, .	2.8	7
705	SARS-CoV-2 Vaccines: The Mucosal Immunity Imperative. <i>Mayo Clinic Proceedings</i> , 2022, 97, 1771-1773.	1.4	6
706	Immunity and infectivity in covid-19. <i>BMJ, The</i> , 0, , e061402.	3.0	11
707	Systematic review of spontaneous reports of myocarditis and pericarditis in transplant recipients and immunocompromised patients following COVID-19 mRNA vaccination. <i>BMJ Open</i> , 2022, 12, e060425.	0.8	9
708	The Promises of Speeding Up: Changes in Requirements for Animal Studies and Alternatives during COVID-19 Vaccine Approval—A Case Study. <i>Animals</i> , 2022, 12, 1735.	1.0	7
709	SARS-CoV-2 Epitopes following Infection and Vaccination Overlap Known Neutralizing Antibody Sites. <i>Research</i> , 2022, 2022, .	2.8	2
710	Circular RNA vaccine, a novel mRNA vaccine design strategy for SARS-CoV-2 and variants. <i>MedComm</i> , 2022, 3, .	3.1	1
712	Cell repopulation dynamics and drug pharmacokinetics impact SARS-CoV-2 vaccine efficacy in anti-CD20-treated multiple sclerosis patients. <i>European Journal of Neurology</i> , 2022, 29, 3317-3328.	1.7	13
713	Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine. <i>Nature Biomedical Engineering</i> , 2022, 6, 791-805.	11.6	100
714	A Complementary Union of SARS-CoV2 Natural and Vaccine Induced Immune Responses. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
715	The Role of Cellular Immunity in the Protective Efficacy of the SARS-CoV-2 Vaccines. <i>Vaccines</i> , 2022, 10, 1103.	2.1	11
716	MiRNA-SARS-CoV-2 dialogue and prospective anti-COVID-19 therapies. <i>Life Sciences</i> , 2022, 305, 120761.	2.0	23
717	Insights into COVID-19 vaccines development: Translation from benchside to bedside. <i>Health Sciences Review</i> , 2022, 4, 100040.	0.6	1
718	Nasal Mucosa Exploited by SARS-CoV-2 for Replicating and Shedding during Reinfection. <i>Viruses</i> , 2022, 14, 1608.	1.5	2
719	mRNA Vaccines Against SARS-CoV-2 Variants Delivered by Lipid Nanoparticles Based on Novel Ionizable Lipids. <i>Advanced Functional Materials</i> , 2022, 32, .	7.8	31
720	Optimized intramuscular immunization with VSV-vectored spike protein triggers a superior immune response to SARS-CoV-2. <i>Npj Vaccines</i> , 2022, 7, .	2.9	7
721	Clinical application of microRNAs in glomerular diseases. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 1375-1384.	0.4	3

#	ARTICLE	IF	CITATIONS
722	Mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-2. <i>Npj Vaccines</i> , 2022, 7, .	2.9	23
723	New insights on circular RNAs and their potential applications as biomarkers, therapeutic agents, and preventive vaccines in viral infections: with a glance at SARS-CoV-2. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 29, 705-717.	2.3	6
724	Vaccines against SARS-CoV-2 variants and future pandemics. <i>Expert Review of Vaccines</i> , 2022, 21, 1363-1376.	2.0	6
725	Current Vaccine Platforms in Enhancing T-Cell Response. <i>Vaccines</i> , 2022, 10, 1367.	2.1	8
726	COVID-19 Vaccine Clinical Trials: A Bird's Eye Perspective. <i>Cureus</i> , 2022, , .	0.2	0
727	Too advanced for assessment? Advanced materials, nanomedicine and the environment. <i>Environmental Sciences Europe</i> , 2022, 34, .	2.6	2
728	Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimera. <i>EBioMedicine</i> , 2022, 82, 104203.	2.7	15
729	Vaccine-associated enhanced respiratory pathology in COVID-19 hamsters after TH2-biased immunization. <i>Cell Reports</i> , 2022, 40, 111214.	2.9	24
730	ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants. <i>Nature Communications</i> , 2022, 13, .	5.8	23
731	Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	15
732	Vaccine-associated enhanced disease in humans and animal models: Lessons and challenges for vaccine development. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	12
733	A platform technology for generating subunit vaccines against diverse viral pathogens. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
734	Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages. <i>Cell Discovery</i> , 2022, 8, .	3.1	13
735	SARS-CoV-2 mRNA-vaccine candidate; CORENAPCINÂ®, induces robust humoral and cellular immunity in mice and non-human primates. <i>Npj Vaccines</i> , 2022, 7, .	2.9	5
736	Recurrence of COVID-19 infection symptoms in short time; reinfection or reactivation? Three cases of three healthcare workers and a literature review. <i>Annals of Medicine and Surgery</i> , 2022, 82, .	0.5	0
737	Accelerating model-informed decisions for COVID-19 vaccine candidates using a model-based meta-analysis approach. <i>EBioMedicine</i> , 2022, 84, 104264.	2.7	4
738	Adjuvants, the Elephant in the Room for RNA Vaccines. <i>RNA Technologies</i> , 2022, , 257-276.	0.2	0
739	Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine. <i>Clinical and Translational Immunology</i> , 2022, 11, .	1.7	2

#	ARTICLE	IF	CITATIONS
740	Clinical Development of mRNA Vaccines: Challenges and Opportunities. <i>Current Topics in Microbiology and Immunology</i> , 2022, , 167-186.	0.7	2
741	Covid-19: Treatment conclusion with kinds of vaccine and drugs. <i>AIP Conference Proceedings</i> , 2022, , .	0.3	0
742	Covid-Associated Pernio is the Product of an Abortive Sars-Cov-2 Infection Resulting in the Deposition of Inflammatory Viral Rna and a Local Interferon Response. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
743	Messenger RNA for Prophylaxis. <i>RNA Technologies</i> , 2022, , 17-40.	0.2	0
744	Viral vector and nucleic acid vaccines against COVID-19: A narrative review. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	14
745	Sodium alginate coating simultaneously increases the biosafety and immunotherapeutic activity of the cationic mRNA nanovaccine. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 942-954.	5.7	8
746	Characteristics and Roles of T Follicular Helper Cells in SARS-CoV-2 Vaccine Response. <i>Vaccines</i> , 2022, 10, 1623.	2.1	2
747	Covid-19 Vaccines â€™ Immunity, Variants, Boosters. <i>New England Journal of Medicine</i> , 2022, 387, 1011-1020.	13.9	266
748	Improvement of native structure-based peptides as efficient inhibitors of protein-protein interactions of SARS-CoV-2 spike protein and human ACE2. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	1
749	Immunogenicity and protective efficacy of a DNA vaccine inducing optimal expression of the SARS-CoV-2 S gene in hACE2 mice. <i>Archives of Virology</i> , 2022, 167, 2519-2528.	0.9	2
751	Saving millions of lives but some resources squandered: emerging lessons from health research system pandemic achievements and challenges. <i>Health Research Policy and Systems</i> , 2022, 20, .	1.1	5
752	Prospects of animal models and their application in studies on adaptive immunity to SARS-CoV-2. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
753	Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	55
754	Immune responses to SARS-CoV-2 infection and COVID-19 vaccines. <i>Exploration of Immunology</i> , 2022, 2, 648-664.	1.7	1
755	Seroconversion rate after COVID-19 vaccination in patients with solid cancer: A systematic review and meta-analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	5
756	Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants. <i>Cell Reports</i> , 2022, 41, 111528.	2.9	6
757	In silico design of refined ferritin-SARS-CoV-2 glyco-RBD nanoparticle vaccine. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	2
758	Delta variant: Partially sensitive to vaccination, but still worth global attention. <i>Journal of Translational Internal Medicine</i> , 2022, 10, 227-235.	1.0	2

#	ARTICLE	IF	CITATIONS
759	Phenylalanine hydroxylase mRNA rescues the phenylketonuria phenotype in mice. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	9
760	Development of variantâ€proof severe acute respiratory syndrome coronavirus 2, panâ€sarbecovirus, and panâ€coronavirus vaccines. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	12
761	A single intranasal administration of AdCOVID protects against SARS-CoV-2 infection in the upper and lower respiratory tracts. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	9
762	A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 27, 309-323.	1.8	14
765	A combination vaccine against SARS-CoV-2 and H1N1 influenza based on receptor binding domain trimerized by six-helix bundle fusion core. <i>EBioMedicine</i> , 2022, 85, 104297.	2.7	11
766	STATUS OF COVID-19 IN THE WORST AFFECTED TWENTY COUNTRIES AND THE WORLD AT THE END OF 2020. <i>Towards Excellence</i> , 0, , 115-135.	0.0	0
767	Dose optimisation and scarce resource allocation: two sides of the same coin. <i>BMJ Open</i> , 2022, 12, e063436.	0.8	5
768	SARS-CoV-2 Vaccines: Types, Working Principle, and Its Impact on Thrombosis and Gastrointestinal Disorders. <i>Applied Biochemistry and Biotechnology</i> , 2023, 195, 1541-1573.	1.4	4
769	Protection from COVID-19 with a VSV-based vaccine expressing the spike and nucleocapsid proteins. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
770	Microfluidic production of mRNA-loaded lipid nanoparticles for vaccine applications. <i>Expert Opinion on Drug Delivery</i> , 2022, 19, 1381-1395.	2.4	15
771	Drug Development Strategies and Immunological Aspects of SARS-CoV-2. <i>Open Public Health Journal</i> , 2022, 15, .	0.1	2
772	Nanotechnology-Driven Delivery Systems in Inoculation Therapies. <i>Methods in Molecular Biology</i> , 2023, , 39-57.	0.4	0
773	Nucleic Acid Vaccines against SARS-CoV-2. <i>Vaccines</i> , 2022, 10, 1849.	2.1	10
774	Promising strategy for developing mRNA-based universal influenza virus vaccine for human population, poultry, and pigsâ€“ focus on the bigger picture. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
775	Immunization with a Prefusion SARS-CoV-2 Spike Protein Vaccine (RBM RNA-176) Protects against Viral Challenge in Mice and Nonhuman Primates. <i>Vaccines</i> , 2022, 10, 1698.	2.1	4
776	Characteristics of animal models for COVIDâ€19. <i>Animal Models and Experimental Medicine</i> , 2022, 5, 401-409.	1.3	7
777	Strategy of developing nucleic acid-based universal monkeypox vaccine candidates. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	17
778	Neutralizing antibodies from the rare convalescent donors elicited antibody-dependent enhancement of SARS-CoV-2 variants infection. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	5

#	ARTICLE	IF	CITATIONS
779	Targeted degradation of PCNA outperforms stoichiometric inhibition to result in programmed cell death. <i>Cell Chemical Biology</i> , 2022, 29, 1601-1615.e7.	2.5	6
780	Naturally occurring spike mutations influence the infectivity and immunogenicity of SARS-CoV-2. , 2022, 19, 1302-1310.		17
781	Zebrafish models of COVID-19. <i>FEMS Microbiology Reviews</i> , 2023, 47, .	3.9	6
782	Intranasal delivery of a chimpanzee adenovirus vector expressing a pre-fusion spike (BV-AdCoV-1) protects golden Syrian hamsters against SARS-CoV-2 infection. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	3
783	Immunogenicity and efficacy of COVID-19 vaccines in people living with HIV: a systematic review and meta-analysis. <i>International Journal of Infectious Diseases</i> , 2022, 124, 212-223.	1.5	21
784	A systematic and thematic analysis of the top 100 cited articles on mRNA vaccine indexed in Scopus database. <i>Human Vaccines and Immunotherapeutics</i> , 0, , .	1.4	2
785	mRNA vaccines for COVID-19. , 2023, , 611-624.		0
786	Intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in monkeys. <i>Cell</i> , 2022, 185, 4811-4825.e17.	13.5	19
787	The role of noncoding RNAs in cancer lipid metabolism. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
789	COVID-19 signalome: Potential therapeutic interventions. <i>Cellular Signalling</i> , 2023, 103, 110559.	1.7	5
790	Immunogenicity of inactivated coronavirus disease 2019 vaccines in patients with chronic hepatitis B undergoing antiviral therapy. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	0
791	Current state of, prospects for, and obstacles to mRNA vaccine development. <i>Drug Discovery Today</i> , 2023, 28, 103458.	3.2	5
792	Advances in Next-Generation Coronavirus Vaccines in Response to Future Virus Evolution. <i>Vaccines</i> , 2022, 10, 2035.	2.1	3
793	Lipid carriers for mRNA delivery. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 4105-4126.	5.7	13
796	Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge 1 year later. <i>Science Translational Medicine</i> , 2023, 15, .	5.8	10
797	Therapeutic Potentials of Immunometabolomic Modulations Induced by Tuberculosis Vaccination. <i>Vaccines</i> , 2022, 10, 2127.	2.1	5
798	Serum antibody profiling identifies vaccine-induced correlates of protection against aerosolized ricin toxin in rhesus macaques. <i>Npj Vaccines</i> , 2022, 7, .	2.9	2
799	Antibodies Induced by Homologous or Heterologous Inactivated (CoronaVac/BBIBP-CoV) and Recombinant Protein Subunit Vaccines (ZF2001) Dramatically Enhanced Inhibitory Abilities against B.1.351, B.1.617.2, and B.1.1.529 Variants. <i>Vaccines</i> , 2022, 10, 2110.	2.1	2

#	ARTICLE	IF	CITATIONS
801	Progress and challenges of mRNA vaccines. , 2023, 1, .		5
802	Emerging toolset of three-dimensional pulmonary cell culture models for simulating lung pathophysiology towards mechanistic elucidation and therapeutic treatment of SARS-CoV-2 infection. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
803	Modulating the expression of tumor suppressor genes using activating oligonucleotide technologies as a therapeutic approach in cancer. <i>Molecular Therapy - Nucleic Acids</i> , 2023, 31, 211-223.	2.3	6
804	Long-term durability of immune responses to the BNT162b2 and mRNA-1273 vaccines based on dosage, age and sex. <i>Scientific Reports</i> , 2022, 12, .	1.6	20
805	Recent developments in the immunopathology of COVID-19. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2023, 78, 369-388.	2.7	33
806	A molecular understanding of alphavirus entry and antibody protection. <i>Nature Reviews Microbiology</i> , 2023, 21, 396-407.	13.6	9
807	Deep learning models for predicting RNA degradation via dual crowdsourcing. <i>Nature Machine Intelligence</i> , 2022, 4, 1174-1184.	8.3	12
809	A genetically engineered, stem-cell-derived cellular vaccine. <i>Cell Reports Medicine</i> , 2022, 3, 100843.	3.3	0
810	The correlation between serum 25-hydroxy-vitamin D levels and anti-SARS-CoV-2 S-RBD IgG and neutralizing antibody levels among cancer patients receiving COVID-19 vaccines. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	4
811	Eliminating Potential Effects of Other Infections during Selection of Nonhuman Primates for COVID-19 Research. <i>Comparative Medicine</i> , 2023, , .	0.4	2
812	A novel mRNA vaccine, SYS6006, against SARS-CoV-2. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	12
814	Updated Insights into the T Cell-Mediated Immune Response against SARS-CoV-2: A Step towards Efficient and Reliable Vaccines. <i>Vaccines</i> , 2023, 11, 101.	2.1	14
815	T Cell Immune Responses against SARS-CoV-2 in the With Corona Era. <i>Biomedical Science Letters</i> , 2022, 28, 211-222.	0.0	0
816	Upper respiratory tract mucosal immunity for SARS-CoV-2 vaccines. <i>Trends in Molecular Medicine</i> , 2023, 29, 255-267.	3.5	17
817	Iterative Design of Ionizable Lipids for Intramuscular mRNA Delivery. <i>Journal of the American Chemical Society</i> , 2023, 145, 2294-2304.	6.6	24
818	A Comprehensive Review of mRNA Vaccines. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2700.	1.8	42
819	Novel Ionizable Lipid Nanoparticles for SARS-CoV-2 Omicron mRNA Delivery. <i>Advanced Healthcare Materials</i> , 2023, 12, .	3.9	11
820	A Review of Bioinformatics for Primatologists: A Note for Reducing Living Primate Model and Supporting the Conservation. , 2023, 1, 1-9.		0

#	ARTICLE	IF	CITATIONS
821	Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	23
822	Safety and immunogenicity of the ChAdOx1, MVA-MERS-S, and GLS-5300 DNA MERS-CoV vaccines. <i>International Immunopharmacology</i> , 2023, 118, 109998.	1.7	1
823	Development and applications of mRNA treatment based on lipid nanoparticles. <i>Biotechnology Advances</i> , 2023, 65, 108130.	6.0	10
824	Cynomolgus Macaque Model for COVID-19 Delta Variant. <i>Immune Network</i> , 2022, 22, .	1.6	2
825	A high-throughput sequencing approach identifies immunotherapeutic targets for bacterial meningitis in neonates. <i>EBioMedicine</i> , 2023, 88, 104439.	2.7	1
826	Role of T cells in severe COVID-19 disease, protection, and long term immunity. <i>Immunogenetics</i> , 2023, 75, 295-307.	1.2	14
827	Employing T-Cell Memory to Effectively Target SARS-CoV-2. <i>Pathogens</i> , 2023, 12, 301.	1.2	0
828	Biophysical Correlates of Enhanced Immunogenicity of a Stabilized Variant of the Receptor Binding Domain of SARS-CoV-2. <i>Journal of Physical Chemistry B</i> , 2023, 127, 1704-1714.	1.2	0
829	Review on COVID-19 Vaccines. <i>Research Journal of Pharmacy and Technology</i> , 2022, , 5868-5874.	0.2	0
830	SARS-CoV-2 S Glycoprotein Stabilization Strategies. <i>Viruses</i> , 2023, 15, 558.	1.5	1
831	mRNA Vaccine - A New Cancer Treatment Strategy. <i>Current Cancer Drug Targets</i> , 2023, 23, 669-681.	0.8	4
832	Monitoring and immunogenicity of SARS-CoV-2 vaccination of laboratory rhesus monkeys (Macaca) Tj ETQq1 1 0.784314 rgBT /Overl	1.6	1
833	Approved Nanomedicine against Diseases. <i>Pharmaceutics</i> , 2023, 15, 774.	2.0	14
834	Comparative pharmacological efficacy of COVID-19 vaccines against the variants of concerns (VOCs) of SARS-CoV-2: Recent clinical Studies on Booster dose. <i>Current Pharmaceutical Biotechnology</i> , 2023, 24, .	0.9	0
835	A comparative study of the COVID-19 vaccine efficacy among cancer patients: mRNA versus non-mRNA. <i>PLoS ONE</i> , 2023, 18, e0281907.	1.1	2
836	Design of a stabilized RBD enables potently neutralizing SARS-CoV-2 single-component nanoparticle vaccines. <i>Cell Reports</i> , 2023, 42, 112266.	2.9	6
838	Vector-based SARS-CoV-2 vaccination is associated with improved T-cell responses in hematological neoplasia. <i>Blood Advances</i> , 0, , .	2.5	1
839	Reviews of drug candidates for COVID-19. , 0, 36, 219-226.		0

#	ARTICLE	IF	CITATIONS
840	Pre-clinical models to define correlates of protection for SARS-CoV-2. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
841	Primates. , 2023, , 679-734.		0
842	Immunology of COVID-19. , 2024, , 52-71.		0
843	TREM2+ and interstitial-like macrophages orchestrate airway inflammation in SARS-CoV-2 infection in rhesus macaques. <i>Nature Communications</i> , 2023, 14, .	5.8	10
844	Revolutionizing viral disease vaccination: the promising clinical advancements of non-replicating mRNA vaccines. <i>Virology Journal</i> , 2023, 20, .	1.4	1
845	Immune Thrombocytopenia Relapse in Patients Who Received mRNA COVID-19 Vaccines. <i>Journal of Blood Medicine</i> , 0, Volume 14, 295-302.	0.7	1
846	SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines. <i>Vaccines</i> , 2023, 11, 849.	2.1	12
849	An RBD virus-like particle vaccine for SARS-CoV-2 induces cross-variant antibody responses in mice and macaques. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	5
870	Knifeâ€™s edge: Balancing immunogenicity and reactogenicity in mRNA vaccines. <i>Experimental and Molecular Medicine</i> , 2023, 55, 1305-1313.	3.2	11
871	Zika Virus Vaccines. , 2023, , 1322-1333.e7.		0
880	mRNA vaccines in disease prevention and treatment. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	9
883	Circular RNA vaccine in disease prevention and treatment. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	3
910	Coagulation and Thrombotic Considerations in Covid-19: Implications for Disease Severity, and Its Vaccines. , 2023, , .		0
915	SARS-CoV-2 biology and host interactions. <i>Nature Reviews Microbiology</i> , 2024, 22, 206-225.	13.6	1
918	mRNA vaccines: a promising solution for incurable diseases. , 2024, , .		0
926	Circular RNAs: Regulators of endothelial cell dysfunction in atherosclerosis. <i>Journal of Molecular Medicine</i> , 2024, 102, 313-335.	1.7	0